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ABSTRACT
Sickness behavior is highly conserved across many species; inflammation causes a variety of
physiological and behavioral changes, including lethargy, decreased social behavior, increased
anxiety, and anhedonia. Many of these behavioral changes are also present in disorders such as
depression and chronic fatigue, which likely have a substantial inflammatory component. While
much is known about the physiology of inflammation, further understanding of neural

mechanisms driving sickness behavior is still needed. One potential modulator of sickness
behavior is arginine vasopressin (AVP), a neuropeptide well known for its contributions to social
and anxiety-like behaviors. AVP is expressed in multiple nuclei that regulate behaviors and
respond to immune activation. We specifically target AVP cells in three of these nuclei: the
paraventricular nucleus of the hypothalamus (PVN), the bed nucleus of the stria terminalis
(BNST), and the suprachiasmatic nucleus (SCN) and test their role in regulating sickness
behaviors. Using genetically modified mice expressing Cre-recombinase in AVP cells, we
selectively ablated AVP cells in these nuclei, followed by tests of lipopolysaccharide (LPS)
induced sickness behavior. Our results indicate that PVN AVP cells regulate changes in
motivation during sickness and contribute to typical anxiety-like behavior; BNST AVP cells
regulate male social behaviors and hedonic behavior in both sexes; and SCN AVP cells regulate
anxiety-like behavior and hedonic behavior in both sexes.
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1
1.1

INTRODUCTION

Inflammation and Sickness Behavior
Sickness is a universal experience among animals. Pathogens infect the body, which must

then mount a response in order to maintain an animal’s health. The immune system is broadly
responsible for this, causing a cascade of physiological and behavioral changes in response to
infection. These behavioral changes during inflammation, known as sickness behavior, are
conserved across species, and serve a function of promoting recovery from infection1,2. Sickness
behaviors include social withdrawal, reduction in activity, anhedonia, and reduced food and
water intake1,3,4. These behavioral changes are similar to those seen in depressive disorders, and
prolonged inflammation and sickness may be one contributing factor and treatment target for
human depression5–7. Further understanding of the neural basis of sickness behavior may provide
more specific targets for treating mental illnesses caused through neuroinflammatory
mechanisms.
One common tool to study sickness behavior is bacterial lipopolysaccharide (LPS), a coat
protein derived from gram-positive bacteria. Injections of LPS simulate bacterial infection and
activate the innate immune system, leading to increased inflammation and sickness behaviors
such as anhedonia, lethargy, reduced social behavior, and increased anxiety-like behavior4,8–10.
LPS is detected by Toll-like receptor 4 (TLR4), a pathogen sensor on innate immune cells, and
triggers production and release of pro-inflammatory cytokines11, the main humoral signaling
molecules of the immune system. The primary pro-inflammatory cytokines released after LPS
challenge are interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNFα),
which are critical for sickness behavior. Administration of these cytokines are effective at
causing sickness behavior12–15, while blocking their receptors inhibits sickness behavior16–21.

2
These cytokines are then sensed by the vagus nerve, other immune cells, and cerebral epithelial
cells to drive neuroinflammatory signaling22,23.
A critical source of inflammatory signaling into the brain, and the primary pathway for
LPS induced sickness behavior, is the vagus nerve22. The vagus nerve receives sensory
information from visceral organs and transmits that information through the spinal cord and into
the brain. In many models of LPS-induced sickness behavior, blocking vagus signaling to the
brain reduces or eliminates behavioral effects of LPS24–29 The vagus nerve detects proinflammatory cytokines30,31, and activates the nucleus of the solitary tract (NTS) and ventral
lateral medulla (VLM) through its hindbrain innervation32,33. The NTS, in concert with the VLM
and parabrachial nucleus (PB), directly activate downstream nuclei via three parallel signaling
pathways: one activating the paraventricular nucleus of the hypothalamus (PVN) and preoptic
nucleus of the hypothalamus (POA), one activating the dorsolateral bed nucleus of the stria
terminalis (BNST) and central amygdala (CeA), and one activating midline thalamus and cortical
structures22,34,35. These nuclei are involved in physiological responses to inflammation; for
example, the BNST, amygdala, and POA regulate fever response36–41 , and the PVN regulates
glucocorticoid release42. While these nuclei are involved in behavioral regulation, much of the
evidence suggesting a role in sickness behavior is circumstantial, such as c-fos activation after
immune challenge32. These regions are likely involved in sickness behavior, but there has not
been enough specific targeting of these nuclei in order to better understand their role in
generating sickness behaviors.
However, the vagal pathway is not the exclusive immune brain interface23. Serum
cytokines can activate receptors on cerebral endothelial cells, as well as bypass the blood brain
barrier in the circumventricular organs43, and then in turn activate microglia and cause cytokine
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release in the brain44. Activated peripheral immune cells may also signal through cerebral
endothelial cells and microglia in order to increase microglia activation and cytokine release45. In
addition to pathogen-mediated inflammatory and sickness response, non-pathogenic and
commissural bacterial, such as those comprising the gut microbiota, signal through these immune
pathways and through production and release of metabolic factors23. All of these pathways may
also induce neuronal changes and contribute to sickness behaviors beyond the nuclei implicated
in vagal-immune signaling.
1.2

Vasopressin Neuroanatomy and Function
Arginine vasopressin (AVP)-expressing cells are a promising target for regulating

behavioral sickness, due to both established function of AVP in regulating behavior and
neuroanatomical position of AVPergic cells. AVP regulates social46,47 and anxiety-like
behaviors48–50, both of which are altered during sickness; additionally, AVP contributes to
physiological aspects of sickness, such as fever38,51 and HPA axis function52. AVP cells in PVN,
BNST, and SCN all have potential to regulate vagal immune pathways and are thus wellpositioned to change behavior in response to inflammation. In this thesis, I test the overarching
hypothesis that AVP in these forebrain nuclei (PVN, BNST, SCN) regulates behavioral
sickness expression in mice by altering anhedonia, anxiety-like behavior, and social
behavior in response to inflammation. This is specifically tested by selectively ablating AVP
cells in each of these nuclei followed by tests of LPS-induced sickness behavior.
1.2.1

Paraventricular Nucleus of the Hypothalamus

PVN AVP is highly likely to regulate sickness behaviors, as these cells receive direct
activation from the NTS after LPS challenge, and increase AVP gene expression and release
during sickness32,53–55. AVP, in conjunction with corticotropin releasing factor (CRF), controls
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the hypothalamic-pituitary-adrenal (HPA) axis, including causing glucocorticoid release42, which
regulates immune responding as an anti-inflammatory signal56. PVN AVP contributes to social
and anxiety behaviors, through HPA axis regulation and projections to the lateral septum (LS),
BNST, CeA, and surrounding hypothalamic nuclei48,57–60. PVN AVP may regulate anxiety-like
and social behaviors via actions in these nuclei. PVN AVP cells are activated during sickness,
and regulate typical behavioral functions; therefore, Chapter 2 tests the hypothesis that PVN
AVP cells contribute to expression of sickness behavior. Specifically, if PVN AVP is
involved in balancing inflammatory processes by increasing glucocorticoid release, or altering
activity via central projections, removal of these cells will enhance sickness behavior.
1.2.2

Bed Nucleus of the Stria Terminalis

While the BNST AVP cells are located in the posteromedial BNST61, separate from the
dorsolateral BNST that receives NTS and PB projections22, BNST AVP has been shown to play
a role in regulating inflammation. In male rats, sex hormone-dependent AVP, primarily from the
BNST, acts in the septal nuclei to reduce fever38,51. Additionally, intracerebroventricular
manipulations of AVP, targeting BNST outputs such as the septum, suggest testosteronedependent AVP reduces sickness behaviors62. BNST AVP is best known for its control of male
social behaviors, which are also regulated by BNST-septal projections. BNST AVP expression is
sexually dimorphic63, and manipulations of BNST AVP changes male social behaviors, with
minimal effects on females64–67. Due to its important role in male social behavior and evidence
that hormone-dependent AVP regulates fever, Chapter 3 tests the hypothesis that BNST AVP
cells contribute to expression of male sickness behavior. If BNST AVP exerts similar effects
on sickness behavior as it does fever, then removal of AVP cells will exacerbate behavioral
sickness in males, with minimal effects in females.

5
1.2.3

Suprachiasmatic Nucleus

SCN AVP cells may regulate sickness behaviors via afferents onto vagal-activated nuclei.
SCN AVP projects to midline thalamus and hypothalamus regions, including the PVN57, which
receive NTS and VLM innervation22. The SCN has a reciprocal relationship with neuroimmune
signals68–71, in which the SCN regulates inflammatory signaling while cytokines alter the activity
of the SCN. The SCN is the central clock of the brain, and rhythms in clock genes organize
physiological and behavioral rhythms, including circadian patterns in the immune system72,73.
Neuroimmune mechanisms that increase cytokine signaling in the brain, such as humoral and
immune-cell mediated signaling23 are the likely source of inflammatory signals to the SCN.
Cytokines such as TNF-a disrupt circadian rhythms by inhibition of the clock gene Per74, and
LPS-induced immune response can cause phase shifts if administered during the dark phase75.
Conversely, the SCN regulates and keeps immune responding in check; light disruption and SCN
lesions cause increased and over responsive reactions to LPS68,76. SCN AVP has been studied
mainly in its contributions to circadian rhythm maintenance. Local AVP release in the SCN
coordinates cellular clocks, and contributes to adjusting to light cycle changes, activity rhythms,
and daily food and water intake77–81. However, AVP in the SCN has not been specifically studied
as a mediator of this clock-immune interface, and it is unknown how disruptions to SCN AVP
affect sickness. LPS has been shown to increase AVP release in SCN cell cultures82, but the role
this may play in sickness regulation is unknown. Additionally, SCN AVP contributions to
baseline social and anxiety-like behaviors have not been characterized, although SCN AVP
projects to nuclei that regulate these behaviors. Chapter 4 tests the hypothesis that SCN AVP
cells contribute to expression of social, anxiety, and sickness behaviors; if SCN AVP release
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is one mechanism by which the SCN regulates immune responding, then removal of these cells
will lead to exacerbated sickness behaviors.
1.3

Hypothesis and Specific Aims
To test the hypothesis that AVP cells regulate expression of sickness behavior, we

directly target AVP-expressing cells. Mutant mice that express Cre-recombinase driven by AVP
promoter, which causes Cre-expression only in AVP cells, were injected in target nuclei with
viral mediated, Cre-dependent caspase. This causes programmed cell death, and selective
ablation of AVP expressing cells with minimal damage to surrounding cells. To test this
hypothesis, AVP cells in these three regions of interest: the PVN (Specific Aim 1), the BNST
(Specific Aim 2), and the SCN (Specific Aim 3), were selectively ablated, followed by tests of
LPS-induced sickness behaviors. Characterization of these behaviors, along with observation of
normative behaviors during healthy conditions, provide further insight into a role for AVP cells
in regulating male social behavior, anxiety behavior in both sexes, and hedonic motivation in
both sexes.
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2

REMOVAL OF VASOPRESSIN CELLS FROM THE PARAVENTRICULAR
NUCLEUS OF THE HYPOTHALAMUS ENHANCES LPS-INDUCED SICKNESS
BEHAVIOR IN MICE

Jack Whylings, Nicole Rigney, Geert J de Vries, Aras Petrulis
JW designed and performed experiments, analyzed data, and wrote manuscript, NR
contributed to performing experiments and data analysis, GJdV and AP contributed to
experimental design, advisement, writing, and provided resources.83
2.1

Abstract
Vasopressin (AVP) cells in the paraventricular nucleus of the hypothalamus (PVN) are

activated during sickness and project to multiple nuclei responsible for anxiety, social, and
motivated behaviors affected during sickness, suggesting that these cells may play a role in
sickness behaviors, typically expressed as reduced mobility, increased anxiety, anhedonia, and
social withdrawal. In this study, we selectively ablated AVP neurons in the PVN of male and
female mice (Mus musculus) and induced sickness behavior via injection of bacterial
lipopolysaccharide (LPS). We found that PVN AVP ablation increased the effects of LPS,
specifically by further decreasing sucrose preference in males and females and decreasing the
social preference of males, monitored within 24 hours of LPS injection. These results suggest
that PVN AVP contributes to the change in motivated behaviors during sickness and may help
promote recovery from infection.
2.2

Introduction
The immune system is one of the main internal defenses of animals against infection.

When the immune system is activated, cytokines are released systemically, body temperature
increases, immune cells migrate to sites of infection and injury, and mobility and social
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interactions are reduced5. While these alterations promote recovery from infection1,
inappropriate or overactive immune responses may contribute to mental health conditions such
as depression, anxiety, PTSD, and chronic fatigue84–87. Indeed, prominent behavioral changes in
sickness involve anhedonia and withdrawal from social stimuli and non-social anxiogenic
stimuli, changes similar to those seen in depression, suggesting that immune activation may play
a role in depression5,88,89. In fact, antidepressants can reduce depression-like components of
sickness behavior triggered by administration of bacterial lipopolysaccharide (LPS), which
supports an inflammatory component of depression90,91. Understanding the brain regions and
circuits that give rise to sickness behavior may give insight what roles these structures may play
in mood disorders.
One structure that may be important in sickness behavior is the paraventricular nucleus of
the hypothalamus (PVN), a critical stress-response region92,93. The PVN receives information on
systemic inflammation most prominently via vagus nerve signaling pathways22,26,28, and is
activated during an immune response, evidenced by immediate early gene expression in the PVN
after LPS administration22,32,54,55. This activation causes increased release of corticotropin
releasing factor (CRF) and vasopressin (AVP)94. These neuropeptides play an important role in
glucocorticoid response to infections, but can also become over-responsive, leading to mental
health deficits and prolonged neuroinflammation95–98.
While the majority of work studying the role of inflammation in depression focuses on
glucocorticoids, AVP is also likely involved in sickness behavior. In rats, LPS activates
the centrally projecting parvocellular AVP cells of the PVN55. Similarly, the actions of central
AVP in the basal forebrain temper fever38. Although the origin of antipyretic AVP action is
thought to be the bed nucleus of the stria terminalis (BNST), the PVN also innervates areas of
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the basal forebrain implicated in fever57,61 and may therefore contribute to the febrile response as
well99. In addition, AVP from the PVN is thought to play a role in modulation of social and
anxiety behaviors in stressful contexts47,58,100,101. For example, hypothalamic AVP expression
strongly correlates with anxiety phenotypes in mice and rats48,49,102, suggesting that AVP from
the PVN may alter social and anxiety-like behaviors during sickness as well. To test the
hypothesis that PVN AVP cells contribute to social and emotional behavioral changes during
sickness, we selectively ablated PVN AVP cells in male and female mice (Mus musculus) and
measured their anxiety-like behavior, anhedonia, social preference and motor activity before and
after challenge with illness-inducing LPS. We found that removing these cells affected
behavioral responses to sickness in both sexes, but more so in males than in females.
2.3

Methods
2.3.1

Animals

All mice were maintained at 22°C on a 12:12 reverse light cycle with food and water
available ad libitum, housed in individually ventilated cages (Animal Care Systems), and
provided with corncob bedding, a nestlet square, and a housing tube. All animal procedures were
approved by the Georgia State University Institutional Animal Care and Use Committee
(IACUC) and were in accordance with the regulations and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
AVP-IRES2-Cre-D (AVP-Cre) mice were obtained from The Jackson Laboratory (Stock
No: 023530). AVP-Cre knock-in mice have Cre recombinase expression directed to AVPexpressing cells that are restricted to populations within the hypothalamus. Subjects were derived
by crossing heterozygous Cre+ mutants to wildtype C57BL/6J mice and genotyped (via ear
punch) by polymerase chain reaction (PCR) at 21-24 days of age (Transnetyx). Both Cre+ and
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Cre- littermates were used in behavioral experiments. A total of 40 experimental animals were
tested: 9 Cre- males, 12 Cre- females, 10 Cre+ males, and 9 Cre+ females. All subjects were
used in a prior study35, and all surgical procedures described below were conducted as part of
that study. In the prior study, behavioral tests were conducted 3-6 weeks after ablation surgery;
in the present study, behavioral tests were conducted 8-10 weeks after the initial ablation
surgery.. Stimulus animals for the three-chamber tests were adult C57BL/6J mice of both sexes,
group-housed in the same room conditions as the experimental animals.
2.3.2

Viral Vectors

AVP promoter-driven-, Cre-expressing PVN neurons were ablated using an adenoassociated virus (AAV serotype 2/1 (3x1012 IU/mL) AAV-flex-taCasp3-TEVp; UNC Vector
Core) that encodes, in a Cre-dependent fashion, a mutated pro-caspase-3 and its activator
(TEVp). This system activates an apoptotic signaling cascade, cleaving multiple structural and
regulatory proteins critical for cell survival and maintenance36,37 and killing cells with far less
collateral inflammation than other lesion approaches35,38.
2.3.3

Stereotaxic surgery

All surgeries were carried out using 1.5-3% isoflurane gas anesthesia in 100% oxygen; 3
mg/kg of carprofen was given before surgery to reduce pain. Mice were positioned in a
stereotaxic frame (David Kopf Instruments) with ear and incisor bars holding bregma and
lambda at level. After a midline scalp incision, a hand-operated drill was used to make holes in
the skull, exposing the dura. For both Cre+ and Cre- subjects, 500 nl of AAV-flex-taCasp3TEVp was delivered bilaterally to the PVN (coordinates: AP -0.42 mm; ML ± 0.35 mm; DV 5.2
mm)39 at a rate of 100 nl/min using a 5 μl Hamilton syringe with a 30-gauge beveled needle
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mounted on a stereotaxic injector. Following virus delivery, the syringe was left in place for 15
min and slowly withdrawn from the brain35.
2.3.4

Experimental Procedure

At least one week after tests for social and communicative behavior described in35,
subjects were weighed and injected intraperitoneally with either 0.5 mg/kg LPS (from e. coli
0111:B4, Millipore-Sigma) or sterile saline one hour before dark phase (ZT11). While the LPS
doses used across studies is highly variable, inflammation and sickness behavior after LPS
administration occurs from 2 hours to over 24 hours post-injection 1,40. Therefore, the open
field test (OFT) was conducted three hours following LPS injections, and the elevated zero maze
(EZM) test was conducted immediately following the OFT. Sucrose preference was then
assessed in the home cage during the following 24-hour period (5 hours after LPS). The day after
LPS or saline injections, the three-chamber social interaction test was conducted during the dark
phase. Animals were tested in all measures twice, first within ~24 hours after LPS/Saline, then
again one week later, receiving both treatments as indicated in Figure 1. In all cases, animals
were acclimated to the behavior testing suite for at least one hour before testing, and behavior
tests were done in the dark phase under red lighting. Manual scoring of behaviors in the EZM
and three-chamber tests was conducted by an experimenter blind to the subjects’ genotype
(Noldus Observer).

Figure 2-1
Timeline of behavioral experiments
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2.3.5

Open-Field and Elevated Zero Maze

Three hours after LPS injections, animals were placed in a 43 cm x 43 cm x 30 cm open
field chamber for 10 min and behavior was automatically tracked via infrared beam breaks (Med
Associates). Distance traveled and time spent in the (anxiogenic) center area were analyzed as
measures of locomotion and anxiety-like behavior, respectively.
Immediately after OFT, subjects were tested on an elevated zero maze (EZM). This
apparatus consists of a 5.5 cm wide circular platform (internal diameter 35 cm) raised 50 cm off
the ground, with two equally spaced enclosed compartments covering half of the platform. Video
was manually scored for time spent in both open and closed arms as a measure of anxiety-like
behavior, and for zone crosses (subject crossing from open to closed arm and vice versa) as a
measure of activity.
2.3.6

Sucrose Preference

For at least 2 days before LPS/saline injections, subjects were acclimated to having two
water bottles placed in their home cage. After OFT/EZM assessment, subjects were returned to
their home cage, and bottles were replaced with pre-weighed bottles, one containing sucrose
solution (2.5% in tap water) and the other tap water. Animals had access to both sucrose solution
and water for the next 20 hours, until the start of the next day’s testing. The bottles were then
removed and weighed to measure consumption. A control water bottle in a nearby empty cage
showed a <1 g loss over the same period and room conditions. Sucrose consumption, water
consumption and preference, calculated as the percentage of sucrose consumed of total
consumption (Sucrose / (Sucrose + Water) *100%), were analyzed.
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2.3.7

Social Preference

To measure social preference and social novelty-preference, animals were tested in a
large plexiglass chamber (20.3 x 42 x 22 cm) divided into three equal compartments with
openings between sections, 26 hours after LPS injection. Subjects were placed in the apparatus
for 5 min before testing in order to habituate the subjects to the environment and were then
temporarily removed while stimulus animals/objects, contained within smaller cages (8 cm
diameter, 18 cm height, 3-mm diameter bars, 7.4 mm spacing) were placed in the center of each
of the two outer chambers. First, to test for social preference, a novel toy object (either a mouse,
robot, or small car figurine) and a novel same-sex stimulus animal were placed in opposite cages.
Subjects and stimulus animals had limited ability to directly contact each other; they were able to
pass extremities (e.g. paws, tail) through the smaller cage bars during investigation. The subjects
were then returned to the apparatus and allowed 10 min to explore the apparatus. At the end of
this test, the subjects were removed again, and the toy object replaced with a novel stimulus
animal (from a different cage from the first stimulus) to test for recognition of social novelty.
The subject was then placed into the center chamber again and given 10 min to explore the
apparatus. The position of object and original animal was counterbalanced across trials but did
not change between social preference and social novelty preference tests. Videos were manually
scored for outer chamber entries as a measure of activity, time spent in each chamber, and active
investigation, defined by the subject’s snout within 2 cm of the stimulus cage.
2.3.8

Histology

After completion of all behavioral testing, animals were sacrificed via CO2 asphyxiation.
Brains were rapidly removed and flash-frozen in 2-methylbutane before storage at -80° C.
Frozen tissue was cut coronally in 20 μm sections, and processed for AVP mRNA fluorescent in
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situ hybridization, as described in detail in Rigney et al.35. Bilateral PVN images were taken
across four sections covering the entire anterior to posterior extent of the PVN; averaged cell
counts per hemisphere were used to estimate percentage of AVP cells ablated.
2.3.9

Data Analysis

Statistical analysis was conducted using SPSS (IBM). OFT, EZM, sucrose preference
test, and social preference data were analyzed using a mixed-model, three-way ANOVA with
treatment (LPS, Saline) as within-subjects variable, and sex (M, F) and genotype (Cre+, Cre-) as
between-subject variables. Results with p-values equal to or less than 0.05 were considered
significant, and results with p-values between 0.05 to 0.09 were considered trends. All data sets
maintained sphericity as determined by Mauchly’s test of sphericity, and thus degrees of freedom
were not adjusted. Post-hoc t-tests were used to analyze genotype and sex differences following
significant or trending ANOVA main effects and interactions. In addition, to analyze the
relationship between PVN AVP cell loss and behavior, Pearson’s correlation coefficients were
calculated using the number of remaining PVN AVP cells/mm2 in Cre+ subjects.
2.4

Results
2.4.1

Removal of AVP Cells in PVN

As described in Rigney et al., Cre+ subjects were considered to have a successful ablation
of PVN AVP cells when more than 60% of cells were removed. Of subjects that met this criteria,
the average ablation percentages for male and female subjects were 73.14 ± 2.67% and 83.11 ±
3.19%, respectively. Figure 2 shows an example of AVP expression in a Cre- subject, which
shows normal distribution of AVP cells, and in a Cre+ subject, which shows significant AVP cell
loss. No correlation between extent of AVP cell ablation and behavior was observed, except
where noted below.
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Figure 2-2
AVP in situ hybridization. Example photomicrographs of PVN AVP cells in (A) Cre- and
(B) Cre+ animals.
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2.4.2

Anxiety-Like Behaviors in Open Field and Elevated Zero Maze

In both the open field test (OFT) and elevated zero maze (EZM), there were strong
effects of LPS, but no main effects or interactions of sex and genotype on either mobility or
anxiety-like behaviors. In the open field test (OFT), LPS treatment significantly reduced total
distance traveled (FLPS = 481.68, p < 0.01, ηp2 = 0.94), indicating reduced locomotion, with a
significant interaction of treatment and sex (FLPS x Sex = 4.39, p = 0.044, ηp2 = 0.12); there
were no main effects or interactions of genotype. To explore the treatment by sex interaction
effect, post-hoc t-tests revealed that males traveled significantly less after saline treatment than
females (t = -2.12, p = 0.042), but the sexes did not differ in locomotion after LPS treatment (t =
0.52, p = 0.61). LPS also reduced time spent in the center area of the open field (F LPS = 115.51,
p < 0.001, ηp2 = 0.78), indicating increased anxiety-like behavior, while no other main effects or
interactions of sex and genotype were observed (Table 1). However, there was a positive
correlation between the number of AVP cells remaining/mm2 in Cre+ males and female subjects
and time spent in the center of the open field after saline treatment ( r = 0.55, p = 0.017), but not
after LPS (r = 0.81, p = 0.749), suggesting that increased PVN AVP cell deletion correlates with
increased anxiety (Figure 3).
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Figure 2-3
Open Field Test. Mean ± SEM of (a) the total distance traveled in the OFT, and (B) time
spent in the center zone of the OFT for Cre- (white bars) and Cre+ (gray bars) male and female
mice after LPS and saline treatments. All data were analyzed in a 3 way mixed-model ANOVA
(Treatment x Genotype x Sex). Points indicate individual data; asterisks indicate significant
effects of LPS treatment. (C) Scatterplot showing the relationship of time spent in the center of
the OFT and AVP cells remaining/mm2 in Cre+ (ablated) animals after both saline (black
points) and LPS (gray points) treatment in males (squares) and females (triangles).
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In the elevated zero maze (EZM) test, LPS treatment significantly reduced both total zone
crosses (F LPS = 54.71, p < 0.001, ηp2 = 0.6), indicating reduced locomotion, with no main
effect or interactions of sex and genotype. LPS also reduced time spent in the open arms of the
EZM (F LPS 40.11, p < 0.001, ηp2 = 0.97), indicating increased anxiety-like behavior, with no
main effects or interactions of sex and genotype (Table 1; Figure 4).

Figure 2-4
Elevated Zero Maze. Mean ± SEM of (a) the number of zone entries in the Elevated Zero
Maze, and (B) time spent in the open arms of the Elevated Zero maze for Cre- (white bars) and
Cre+ (gray bars) mice after LPS and saline treatments. All data were analyzed in a 3 way
mixed-model ANOVA (Treatment x Genotype x Sex). Points indicate individual data; asterisks
indicate significant effects of LPS treatment.
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2.4.3

Sucrose Preference Test

Treatment with LPS as well as genotype altered sucrose preference (F LPS = 41.686, p <
0.01, ηp2 = 0.54; F Genotype = 5.8, p = 0.021, ηp2 = 0.14) with a trending interaction between
treatment and sex (F Treatment x sex = 3.190, p = 0.083) and no other main effects or
interactions (Table 1). A post-hoc t-test for LPS treatment confirmed that LPS reduced
preference for sucrose (t = -6.27, p < 0.001). Post-hoc tests for genotype indicated no difference
between genotypes when treated with saline but did show that LPS reduced preference for
sucrose more in Cre+ than in Cre- animals (t = 2.082, p = 0.044). Post-hoc t-tests for sex
indicated no sex differences in sucrose preference after either saline (t = -1.40, p = 0.17) or LPS
(t = 1.11, p = 0.27) treatment (Figure 5).
Changes in sucrose preference was not due to changes in water consumption, as there
were no differences between treatment conditions or genotype in amount of water consumed
(Table 1), although there was a trending interaction of LPS treatment and sex ( F Treatment x
Sex = 3.49, p = 0.07). Specifically, while there was no sex difference in water consumption after
saline treatment (t = 0.41, p = 0.69), males consumed less water than females following LPS
treatment (t = -2.15, p = 0.038).

20

Figure 2-5
Sucrose preference. Mean ± SEM of the percentage of sucrose solution consumed out of
total fluid consumption (sucrose + water) for Cre- (white bars) and Cre+ (gray bars) mice after
LPS and saline treatments. All data were analyzed in a 3 way mixed-model ANOVA (Treatment x
Genotype x Sex). Points indicate individual data. Asterisks represent significant effects of
treatment and genotype.

2.4.4

Social preference test

In the social preference test, when animals were given a choice between a conspecific
and an object, there were no main effects of treatment, genotype, or sex on preference for the
animal stimulus (Table 1), but there was a significant treatment by genotype interaction in the
percentage of time investigating the stimulus animal compared to the object (F LPS x Genotype
= 6.8, p = .013, ηp2 = 0.16). Post-hoc analysis for genotype revealed that Cre+ animals have less
preference for an animal after LPS treatment (t = 2.07, p = 0.047), but not after saline treatment
(t = -0.61, p = 0.54). To further examine potential influence of sex, exploratory post-hoc t-tests
were performed, which showed a trend of Cre+ males reducing preference for an animal over an
object after LPS treatment (t = 2.12, p = 0.058), whereas females maintained their preference (t =
0.72, p = 0.48; Figure 6). This suggests that the effect of genotype is primarily driven by males,
but not strongly enough to generate a significant interaction of sex by genotype.
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In the social novelty preference test, in which the object was replaced with a novel
conspecific, there were no main effects of treatment, genotype, or sex on preference for the novel
animal (Table 1; Figure 6). Using zone entries as an indicator of activity, LPS reduced activity in
both social preference and social novelty preference tests (F = 124.27, p < 0.001, ηp2 = 0.78),
with a trend towards a treatment x sex interaction (F = 3.314, p = 0.077). Post-hoc t-tests did not
reveal a sex difference in zone crosses in either LPS-treated (t = 1.52, p = 0.14) or saline-treated
(t = -0.45, p = 0.65) animals (Figure 7).

Figure 2-6
Social preference. (A) Mean ± SEM of the percentage of time spent investigating an
animal to total time investigating animal and object stimuli in the three-chamber apparatus of
Cre- (white bars) and Cre+ (gray bars) male and female mice after LPS and saline treatments.
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(B) Mean ± SEM of the percentage of time spent investigating a novel animal to total time
investigating the novel and original animal of Cre- (white bars) and Cre+ (gray bars) mice after
LPS and saline treatments. All data were analyzed in a 3 way mixed-model ANOVA (Treatment x
Genotype x Sex). Points indicate individual data. Asterisk represents a significant effect of
treatment and genotype.

Figure 2-7
Zone crosses in 3 chamber preference test. Mean ± SEM of zone crosses in both the
social preference and social novelty preference phases of the three-chamber test combined of
Cre- (white bars) and Cre+ (gray bars) mice after LPS and saline treatments. All data were
analyzed in a 3 way mixed-model ANOVA (Treatment x Genotype x Sex). Points indicate
individual data. Asterisks represent significant effects of LPS treatment.

Table 2-1

OFT
Distance Traveled
LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1,33) = 481.68
F (1,33) = 1.84
F (1,33) = 2.46
F (1,33) = 1.12
F (1,33) = 4.39
F (1,33) = 0.684

p < 0.001
p = 0.185
p = 0.13
p = 0.3
p = 0.044
p = 0.41

F (1,33) = 2.48

p = 0.125

LPS
Genotype
Sex

F (1,33) = 115.51
F (1,33) = 0
F (1,33) = 0.054

p < 0.001
p = 0.99
p = 0.82

Time in Center
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LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1,33) = 1.71
F (1,33) = 0.13
F (1,33) = 0.13

p = 0.2
p = 0.72
p = 0.72

F (1,33) = 0.33

p = 0.57

LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 54.71
F (1, 36) = 0
F (1, 36) = 0.355
F (1, 36) = 0.63
F (1, 36) = 1.65
F (1, 36) = 0.12

p < 0.001
p = 0.99
p = 0.55
p = 0.8
p = 0.21
p = 0.73

F (1, 36) = 0.86

p = 0.36

LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 40.11
F (1, 36) = 0.071
F (1, 36) = 1.27
F (1, 36) = 0.46
F (1, 36) = 0.38
F (1, 36) = 0.4

p < 0.001
p = 0.79
p = 0.27
p = 0.5
p = 0.85
p = 0.84

F (1, 36) = 0.48

p = 0.49

LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 41.686
F (1, 36) = 5.8
F (1, 36) = 0.42
F (1, 36) = 2.7
F (1, 36) = 3.19
F (1, 36) = 0.63

p < 0.001
p = 0.021
p = 0.52
p = 0.11
p = 0.083
p = 0.43

F (1, 36) = 0.004

p = 0.95

LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 2.51
F (1, 36) = 0.98
F (1, 36) = 1.57
F (1, 36) = 0.029
F (1, 36) = 3.49
F (1, 36) = 0.221

p = 0.12
p = 0.76
p = 0.22
p = 0.87
p = 0.07
p = 0.641

F (1, 36) = 0.21

p = 0.64

EZM
Zone Crosses

Time in Open Arms

Sucrose Preference
Preference (%)

Water Consumed

3 chamber test
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Social Preference
LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 1.24
F (1, 36) = 2.06
F (1, 36) = 2.65
F (1, 36) = 6.8
F (1, 36) = 2.67
F (1, 36) = 0.97

p = 0.27
p = 0.16
p = 0.11
p = 0.013
p = 0.11
p = 0.33

F (1, 36) = 2.25

p = 0.14

LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 1.62
F (1, 36) = 0.17
F (1, 36) = 1.79
F (1, 36) = 0.85
F (1, 36) = 0.071
F (1, 36) = 0.46

p = 0.21
p = 0.68
p = 0.19
p = 0.36
p = 0.79
p = 0.5

F (1, 36) = 0

p = 0.99

LPS
Genotype
Sex
LPS x Genotype
LPS x Sex
Genotype x Sex
LPS x Genotype x
Sex

F (1, 36) = 124.27
F (1, 36) = 0.37
F (1, 36) = 0.29
F (1, 36) = 0.64
F (1, 36) = 3.314
F (1, 36) = 2

p < 0.001
p = 0.55
p = 0.6
p = 0.43
p = 0.077
p = 0.17

F (1, 36) = 0.25

p = 0.62

Social Novelty
Preference

Zone Crosses

2.5

Discussion
In this study, we tested the role of PVN AVP cells in modulating sickness behaviors and

found that removal of these cells exacerbated LPS effects on anhedonia in both sexes, as
measured by reduced sucrose consumption, and on social preference, which was eliminated in
males but not in females. Removal of PVN AVP cells also modestly increased anxiety-related
behavior in the open field test (OFT), in line with an increase of anxiety previously demonstrated
in these animals103. However, we did not detect a role of PVN AVP cells in modulating anxiety-
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like behaviors in other tests of anxiety either at baseline or during sickness. These data suggest
that PVN AVP cells may normally reduce sickness effects on positively valenced behaviors
(sucrose consumption, social interaction), but have less impact on negatively valenced behavior
(anxiety-like behaviors).
We cannot conclude that the effects of PVN AVP cell ablation on behavior are solely due
to the elimination of AVP transmission from those cells. This study eliminated entire cells,
which do contain and release more than AVP. For example, these cells may also release
glutamate, CRF, galanin, and other neurotransmitters58,104–108. CRF, which is increased after LPS
administration109–111, contributes to a rise in glucocorticoid release in sickness along with AVP.
However, these peptides are produced in mostly separate cell populations in unstressed mice112.
Moreover, PVN CRF cell deletion reduces anxiety behaviors113, whereas our male subjects
showed increased anxiety in the current study and in previous tests in our laboratory103,
suggesting that our results cannot be explained by a loss of CRF cells. Nevertheless, the loss of
other non-AVP signals from PVN could contribute to our results; this could be tested in future
experiments with more specific targeting of AVP production.
Additionally, PVN AVP populations are heterogenous and consist of median eminence
and pituitary-projecting cells as well as centrally projecting cells63,112 As cell ablation did not
discriminate for any subtype of PVN AVP cells, we cannot limit interpretation of the results to
ablation of one set of these cells. Remaining PVN AVP cells or other populations may also
compensate for the loss of these cell types and reduce potential effects of ablation. For example,
given our results that show no effect of PVN AVP cell ablation on water intake under baseline or
LPS conditions, and previous data in these animals that showed no difference in urine output103,
we do not believe that cell ablation noticeably affected overall fluid balance, potentially because
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other sources of peripheral AVP such as the supraoptic nucleus and, possibly, remaining PVN
AVP cells may have compensated for the loss of neurosecretory AVP cells in the PVN. We
cannot exclude that ablation of PVN AVP cells did not affect physiological indicators of sickness
,as measuring body temperature or collecting blood would have introduced additional stressors,
which would confound behavioral analysis.
We did not observe a strong effect of PVN AVP cell ablation on anxiety-like behavior in
saline-treated mice, even though we did see an increase in anxiety-like behavior in an elevated
plus maze test in males in an earlier study with these mice103. This discrepancy may be explained
by differences in anxiogenesis of different tests114 and/or the timing of testing. In our previous
study, we tested anxiety-like behaviors prior to all other behavioral tests103 in order to minimize
effects of repeated handling on anxiety measures115,116. Consequently, the testing and handling
before LPS injections in the current study may have reduced the anxiogenicity of the OFT and
elevated zero maze (EZM) in later tests, which may explain why we observed less strong effects
of ablation on anxiety. Nevertheless, we did observe a positive correlation between the degree of
PVN AVP cell ablation and avoidance of the anxiogenic center of the OFT, which supports a
role for these cells in anxiety-like behavior.
Even though we did not find that deletion of PVN AVP cells significantly enhanced the
effects of LPS treatment on anxiety-like behaviors in the OFT or EZM, we cannot exclude a role
for these cells in reducing anxiety-like behavior during sickness. If, in this study, LPS-induced
increases in anxiety-like behavior reached a ceiling level in our subjects, ablation may not have
been able to further enhance the increase in anxiety caused by LPS. A milder immune stimulus
might reveal effects of AVP cell ablation on these tasks. Alternatively, PVN AVP cells may have
a time-dependent effect on sickness expression. In the EZM and OFT, which were performed 3
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hours after LPS injection, only the effects of LPS and not cell ablation were observed. In
contrast, cell ablation enhanced LPS effects during the overnight sucrose preference test and the
social behavior tests performed 24 hours after LPS administration. It is, therefore, possible that
sickness behavior may have been less severe during these later measures, allowing for detection
of sickness behavior-enhancing ablation effects. Conversely, PVN AVP cells may act later in
sickness to promote recovery. Future experiments would be needed to explore PVN AVP effects
on sickness progression and recovery.
The effects of PVN AVP cell deletion were most pronounced on positively valenced
behaviors: the non-social motivation to consume sucrose and the social motivation to investigate
a conspecific. These cells are well-positioned to effect reward circuitry and social behavior,
leading to behavioral changes during sickness. PVN AVP cells project to reward and saliencesensitive regions such as the nucleus accumbens (NAc)57,117, in which AVP increases during
drug taking and cocaine-place preference118–120. The PVN also interacts with the social behavior
neural network121–123, and is one source of AVP afferents to the lateral septum57 and therefore
may contribute to septal AVP effects on social interaction and aggression65,100,124,125 as well as
fever regulation in males126–128. However, behavioral effects of cell ablation in this study were
seen only after LPS injection, not under control saline conditions, suggesting that PVN AVP
input may not significantly modulate positively valenced behavior under normal circumstances,
but is instead involved in adjusting these behaviors in contexts such as sickness. As the
expression of sickness behavior can change depending on social context129 and motivational
states130, PVN AVP and its outputs may integrate social and motivational context to adjust
sickness behaviors.
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Removal of PVN AVP cells lowered social motivation after LPS, but only in males.
Given that AVP exerts sex-dependent effects on social behavior, typically stronger in males than
in females50, our results are consistent with reported sex differences in AVP function. AVP
effects on fever are also male-biased: AVP, presumed to be derived from the male-biased AVP
cell populations in the BNST and MeA, acts in the septal area to reduce fever in males only51,62.
BNST AVP cells contribute to baseline sex differences in social behavior, but do not affect LPSinduced changes131,132. Conversely, we found no baseline changes in social preference after PVN
AVP cell ablation, but did find that these ablations changed social preference, but only in LPStreated male mice. Even though PVN AVP expression as a whole is neither strongly sexually
dimorphic103 nor the main source of AVP to areas like the septal region involved in social
behavior57, our results confirm sexually different impacts of PVN AVP cells on behavior. For
example, PVN AVP cell ablations only enhanced male, but not female, anxiety-like behavior103.
The results of the current study suggest that PVN AVP projections may interact with AVP
projections from other sources, such as the BNST, to contribute to the sex difference in social
behavior we observed.
Sickness enhances anxiety-related behaviors as well as reduces positively motivated
behaviors. Our results identify PVN AVP cells as modulators of appetitive behaviors during
sickness, such as the anhedonic reduction in sucrose intake133,134. In rodents, hypothalamic AVP
expression increases in response to inflammation22,32, and our results indicate that a loss of PVN
AVP enhances anhedonia. This suggests a modulatory role for PVN AVP during sickness in
opposing the loss of positive motivation, similarly to how AVP reduces febrile response during
sickness38,126,135. Anhedonia during sickness resembles anhedonia observed in melancholic
depression in humans, which can have an inflammatory component136–138. An increase of PVN
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AVP during both sickness and depression may counter a loss of motivated behaviors during
illness, and suggest a potential role of PVN AVP cells in modulating anhedonia in models of
depression.
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SEXUALLY DIMPORPHIC ROLE OF BNST VASOPESSIN CELLS IN SICKNESS
AND SOCIAL BEHAVIOR IN MALE AND FEMALE MICE
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3.1

Abstract
Circumstantial evidence supports the hypothesis that the sexually dimorphic vasopressin

(AVP) innervation of the brain tempers sickness behavior in males. Here we test this hypothesis
directly, by comparing sickness behavior in animals with or without ablations of BNST AVP
cells, a major source of sexually dimorphic AVP in the brain. We treated male and female AVPiCre+ and AVP-iCre- mice that had been injected with viral Cre-dependent caspase-3
executioner construct into the BNST with lipopolysaccharide (LPS) or sterile saline, followed by
behavioral analysis. In all groups, LPS treatment reliably reduced motor behavior, increased
anxiety-related behavior, and reduced sucrose preference and consumption. Male mice, whose
BNST AVP cells had been ablated (AVP-iCre+), displayed only minor reductions in LPSinduced sickness behavior, whereas their female counterparts displayed, if anything, an increase
in sickness behaviors. All saline-treated mice with BNST AVP cell ablations consumed more
sucrose than did control mice, and males, but not females, with BNST AVP cell ablations
showed reduced preference for novel conspecifics compared to control mice. These data confirm
that BNST AVP cells control social behavior in a sexually dimorphic way, but do not play a
critical role in altering sickness behavior.
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3.2

Introduction
Most animals experience pathogen-induced sickness during their lifetime. While each

pathogen brings its own set of inflammatory responses and other symptoms, sickness often
causes general behavioral changes such as lethargy, reduced ingestive behavior, and social
withdrawal 3. These behavioral changes are generally thought to complement physiological
responses, such as fever, in speeding up recovery 1. While such behavioral changes may be
beneficial for survival, long-term or inappropriate inflammation may contribute to mental health
conditions such as depression 139. Consequently, understanding the ways in which inflammation
alters behavior may help treat such conditions.
The physiological basis of sickness behavior involves multiple pathways that relay
information about peripheral inflammation, such as vagus nerve activity and humoral immune
signaling 23. Ultimately, peripheral inflammation activates brain regions such as the
paraventricular hypothalamus (PVH), medial amygdala (MeA), bed nucleus of the stria
terminalis (BNST), and preoptic area 22,32, all of which have been associated with behavioral
profiles altered during sickness 8,54,140.
Some of these areas, such as the posterior BNST and MeA, contain arginine vasopressin
(AVP) cells that have been indirectly implicated in regulating fever and sickness behavior 10,38,51.
For example, in rats, fever increases BNST neuronal activity 141, and electrical stimulation of the
BNST reduces fever 142. This may be due to effects of AVP in the septum, a target of
BNST/MeA AVP projections, as septal AVP administration also reduces fever. This effect is
testosterone-dependent, and is found in males but not in females 51,143, mirroring the sex
differences in BNST AVP expression, which is more pronounced in males than in females 63,
which suggest that BNST AVP cells modulate the fever response.
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The same cells may also regulate sickness behavior. For example, in male rats
intracerebroventricular injections of AVP reduce sickness behavior, whereas AVP antagonism
exacerbates sickness behavior 62. These effects are also testosterone-dependent; effects of
inflammation and AVP administration are more pronounced in castrated animals, which cease to
produce AVP in the BNST 62,63. However, whether BNST AVP cells modulate sickness behavior
has not been directly tested. We do so here by selectively ablating AVP cells in the BNST of
male and female AVP-iCre mice via injections of viral vector containing a Cre-dependent cell
death construct (caspase-3/Tev) and testing effects of ablation on sickness behavior. We induced
sickness behavior via intraperitoneal injections of lipopolysaccharide (LPS), a component of
gram-negative bacterial cell walls, commonly used as a proxy for bacterial infections 144,
followed by tests for behaviors altered in sickness. We predicted that BNST AVP cell ablation
would intensify sickness behavior, more so in males than in females.
3.3

Methods
3.3.1

Animals

All mice were maintained at 22°C on a 12:12 reverse light cycle with food and water
available ad libitum, housed in individually ventilated cages (Animal Care Systems), and
provided with corncob bedding, a nestlet square, and a housing tube. All animal procedures were
approved by the Georgia State University Institutional Animal Care and Use Committee
(IACUC) and were in accordance with the National Institutes of Health Guide for the Care and
Use of Laboratory Animals.
Founding AVP-iCre mice were obtained from Dr. Michihiro Mieda (Kanazawa
University, Japan). These mice were generated using a bacterial artificial chromosome that
expressed codon-improved Cre recombinase 145 under the transcriptional control of the AVP
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promoter (AVP-iCre mice). In these animals, iCre expression is found in the bed nucleus of the
stria terminalis and the medial amygdala, as well as in hypothalamic areas 77. Subjects were
derived by crossing heterozygous iCre+ mutants to wildtype C57Bl/6J mice and genotyped (ear
punch) by polymerase chain reaction (PCR) at 21-24 days of age (Transnetyx). Both iCre+ and
iCre- littermates were used in behavioral experiments. All subjects were used in a prior
experiment 131 and all surgical procedures described below were conducted as part of that study.
Stimulus animals for the three-chamber test were adult C57B6/J mice of both sexes, group
housed in the same room conditions as the experimental animals.
In total, 45 animals with confirmed BNST AVP cell ablation 131 were used for the
behavioral testing described below: 11 Cre- males, 13 Cre – females, 13 Cre+ males, and 8 Cre+
females. Two female subjects (1 Cre+ and 1 Cre-) did not recover from initial LPS treatment and
were euthanized and removed from all analyses. The remaining 43 animals were tested on all
behavioral measures described below. Video recording error forced removal of 1 Cre+ female
from the tail suspension test, and removal of 1 Cre+ and 1 Cre- female from the three-chamber
social test analyses. Bottle failure and fluid leakage forced the removal of 6 females (5 Cre-, 1
Cre+) from the sucrose preference analysis.
3.3.2

Viral Vectors

BNST neurons with AVP promoter-driven Cre-expression were ablated using an adenoassociated virus (AAV-flex-taCasp3-TEVp) (University of North Carolina at Chapel Hill Vector
Core) that encodes Cre-dependent pro-caspase-3. This enzyme activates an apoptotic signaling
cascade, cleaving multiple structural and regulatory proteins critical for cell survival and
maintenance 146,147 and thereby inducing far less inflammation than other lesion approaches 148.
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High titer AAV of serotype 2/1 (3×1012 IU/mL) was purchased from the University of North
Carolina at Chapel Hill Vector Core 131.
3.3.3

Stereotaxic surgery

All surgeries were carried out using 1.5-3% isoflurane gas anesthesia in 100% oxygen; 3
mg/kg of carprofen was given before surgery to reduce pain. Mice were positioned in a
stereotaxic frame (David Kopf Instruments) with ear and incisor bars holding bregma and
lambda level. After a midline scalp incision, a hand operated drill was used to make holes in the
skull, exposing the dura. For all subjects, 500 nl of AAV-flex-taCasp3-TEVp was delivered
bilaterally to the BNST (coordinates: AP -0.01 mm; ML ±0.75 mm; DV 4.8 mm 149 at a rate of
100 nl/min using a 5 μl Hamilton syringe with a 30-gauge beveled needle mounted on a
stereotaxic injector. Following virus delivery, the syringe was left in place for 15 minutes and
slowly withdrawn from the brain 131.
3.3.4

Experimental Procedure

All behavior tests were done in the dark phase under red lighting, and animals were
acclimated to the behavior testing suite for at least one hour before testing. At least one week
after tests for social and communicative behavior described in 131 and seven weeks after viral
ablation, subjects were weighed and injected intraperitoneally with either 1 mg/kg LPS (from e.
coli 0111:B4, Millipore-Sigma) or sterile saline one hour before dark phase (ZT11). While the
LPS dose used is highly variable across previous studies, inflammation and sickness behavior
after LPS administration have generally been reported to occur from 2 hours to over 24 hours
post-injection 5,9, and the dose of LPS used in this study reliably induces sickness behavior 8.
Therefore, the open field test (OFT) was conducted three hours following LPS or saline
injections, and the elevated zero maze (EZM) test was conducted immediately following the
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OFT. Sucrose preference was then assessed in the home cage over a 20-hour period, starting 5
hours after LPS or saline injections). Immediately following this (25 hours post-injection),
animals were tested in the three-chamber social interaction test and tail suspension test (TST).
This entire sequence was repeated one week later, with animals that first received LPS now
receiving saline and vice versa as indicated in Fig. 1. An interval of one week between
treatments was chosen, because LPS causes sickness for only up to four days post-injection 150.
To make sure there were no residual effects of the initial LPS treatment results were compared
across treatment order.

Figure 3-1
Experimental Timeline

3.3.5

Open-Field and Elevated Zero Maze

Three hours after injections, animals were placed in an 43cm x 43cm x 30cm open field
chamber for 10 min and behavior was automatically tracked (Med Associates). Data was
analyzed in two 5-min blocks, to separate behavior during the initial exploration period (first 5min block, early exploration phase) from behavior after habituation to the chamber (second 5min block, late exploration phase) 151,152. Distance traveled and time spent in the center area were
analyzed as measures of locomotion and anxiety-like behavior, respectively.
Immediately after OFT, subjects were tested on an elevated zero maze (EZM). This
apparatus consists of a 5.5 cm wide circular platform of internal diameter 35 cm raised 50 cm off
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the ground, with two equally spaced enclosed compartments covering half of the platform.
Subject activity was tracked using automated software (AnyMaze) with the time and speed in
each zone (closed, open), total distance traveled, and immobility time recorded.
3.3.6

Sucrose Preference

For at least 2 days before LPS/saline injections, subjects were acclimated to having two
water bottles placed in their home cage. After OFT/EZM assessment, approximately 5 hours
after LPS injections, subjects were returned to their home cage, and bottles were replaced with
pre-weighed bottles, one containing sucrose solution (2.5% in tap water) and the other tap water.
Animals had access to both sucrose solution and water for the next 20 hours, until the start of the
next day’s testing. The bottles were then removed and reduction in liquid was measured. A
control water bottle in a nearby empty cage showed a <1 mL loss over the same period and room
conditions. Preference was calculated as the percentage of sucrose consumed compared to total
consumption (Sucrose / (Sucrose + Water) *100%).
3.3.7

Social Preference

To measure social preference and social novelty-preference, animals were tested in a
large plexiglass chamber (20.3 x 42 x 22 cm) divided into three equal compartments with
openings between sections, 26 hours after LPS injections. Subjects were habituated to the
apparatus for 5 min before testing. Subjects were temporarily removed while stimuli, contained
within smaller cages (8cm diameter, 18cm height, 3-mm diameter bars, 7.4mm spacing) were
placed in the center of each of the two outer chambers. First, to test for social preference, a novel
toy object and a novel, same-sex stimulus animal were placed in opposite cages. Subjects and
stimuli animals had limited ability to directly contact each other; they were able to pass
extremities (e.g. paws, tail) through the smaller cage bars during investigation. The subjects were
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then returned to the apparatus and allowed 10 minutes to explore the apparatus. At the end of this
test, the subjects were removed again, and the toy object replaced with a novel same-sex
stimulus animal (from a different cage from the first stimulus) to test for recognition of social
novelty. The subject was then placed into the center chamber again and given 10 minutes to
explore the apparatus. The position of object and original animal was counterbalanced across
trials but did not change between social preference and social novelty preference tests. Each trial
was video-recorded, and the time spent in each chamber and in active investigation, defined by
the subject’s snout within 2 cm of the stimulus cage were manually scored from video files
(Noldus Observer) by an experimenter blind to the subjects’ genotype.
3.3.8

Tail Suspension

After the social preference/novelty tests, subjects underwent a 5-minute tail suspension
test (TST) as a measure of stress-coping behavior 153. Time spent hanging immobile (not
struggling) was scored as was latency to first immobile period. Animals were suspended by their
tails by a strip of tape (~15cm) attached to an overhang, during which they were recorded and
later scored (Noldus Observer) by an experimenter blind to the genotype of the subjects.
3.3.9

Tissue Collection and FISH

After completion of all testing, animals were sacrificed via CO2 asphyxiation. Brains
were rapidly removed and flash frozen in 2-methylbutane before storage at -80° C. Frozen tissue
was sectioned coronally in 20μm sections, and processed for AVP mRNA fluorescent in situ
hybridization (FISH) to confirm AVP cell deletion, as described in detail in Rigney et al. (2019).
Ablation was specific to AVP cells in the BNST with no indication of non-targeted cell loss in
the BNST. Nearby AVP hypothalamic cell populations were intact. Only data from subjects with
confirmed BNST ablation (defined as over 90% AVP cell loss) were analyzed in this report.
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3.3.10 Data Analysis
Statistical analysis was conducted using SPSS (IBM). OFT, EZM, Sucrose preference
test, and TST, data was analyzed using a mixed-model three-way ANOVA. Treatment (LPS,
Saline) was the within-subjects variable; both sex (M, F) and genotype (Cre+, Cre-) were the
between-subject variables. Post-hoc t-tests were used to analyze genotype effects following
significant ANOVA interactions. The social preference data was analyzed using a mixed-model
three-way ANOVA with chamber (stimulus 1, stimulus 2) as a within-subjects variable, sex (M,
F) as a between-subjects variable, and genotype (Cre+, Cre-) as a between-subjects variable. This
analysis was performed for each treatment (LPS, Saline) separately, in order to better analyze the
impact of genotype and sex on social investigation.
3.4

Results
3.4.1

Open Field Test and Elevated Zero Maze

LPS caused acute sickness behavior in all animals, with some specific measures affected
by sex and genotype. As expected 8,154, LPS injections decreased the overall distance traveled in
the OFT by all subjects, in both early exploration (FTreatment 1,39 = 396.29 , p < 0.001, ηp2 = 0.91)
and late exploration phases (FTreatment 1,39 = 309.54, p < 0.001, ηp2 = 0.89); no other differences
were apparent (Fig 2A, B).
LPS treatment did not affect time spent in the center zone during the early exploration
phase of the OFT (FTreatment 1,39 = 0.45, p= 0.51) (Fig 2C) but did decrease time spent in the
anxiogenic center zone during the late exploration phase in the OFT test (FTreatment 1,39 = 74.847, p
< 0.001, ηp2 = 0.66) (Fig 2D). There were no genotype or sex effects on any other measures.
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Figure 3-2
Open field behavior. Mean ± SEM of total distance (cm) traveled in the early (A) and late
(B) exploration phases, and of time (seconds) spent in the center of the open field in early (C)
and late (D) exploration phases for male and female Cre- (white bars) and Cre+ (filled bars)
mice. Points indicate individual data. Horizontal bars indicate significant differences between
treatments.

In the elevated zero maze, LPS treatment decreased distance traveled (FTreatment 1,39 =
285.55, p < 0.001, ηp2 = 0.88) with an interaction of Treatment by Sex by Genotype (F1, 39 =
4.723, p = 0.036, ηp2 = 0.108). Post hoc comparisons for effects of genotype trended towards
decreased distance in Cre+ females as compared to Cre- females after LPS treatment (t = 2.17, p
= 0.052), but no obvious differences between Cre+ and Cre- males after LPS treatment (t = 1.11, p = 0.28). There were no apparent differences between genotypes for saline treated males (t
= 0.27, p= 0.98) or females (t = -0.99, p = 0.35) (Fig 3A).
LPS treatment decreased time spent in the anxiogenic open arms (F1,39 = 30.37, p <
0.001, ηp2 = 0.44), with an interaction of Treatment by Sex (FTreatment x Sex 1,39 = 0.47, p= 0.037, ηp2
= 0.107). No other effects or interactions were detected (Fig 3B). LPS injections decreased
subjects’ speed in the open arms (F1,39 = 31.50, p < 0.001, ηp2 = 0.48) in a manner dependent on
sex and genotype (FTreatment x Genotype x Sex 1,39 = 11.668, p = 0.001, ηp2 = 0.23; FGenotype x Sex 1,39 =
5.343, p = 0.026, ηp2 = 0.12). Post-hoc comparisons for genotype revealed that in LPS-treated
subjects, Cre+ males move faster than Cre- males (t=-2.8, p=.017), while Cre+ females move
slower than Cre- females (t= 2.52, p = 0.022). No differences in genotype were detected in saline
treated males (t = 0.69, p= 0.50) or females (t = -0.47, p = 0.64) (Fig 3C), suggesting that
ablating AVP cells does not affect overall activity levels.
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Figure 3-3
Elevated zero maze behavior. Mean ± SEM of (A) total distance traveled (cm), (B) time
spent (seconds) in open arms of the maze, and (C) average speed (cm/seconds) in the open arms
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of the maze for male and female Cre- (white bars) and Cre+ (filled bars) mice. Points indicate
individual data. Horizontal bars indicate treatment differences and genotype differences.

3.4.2

Sucrose Preference and Tail Suspension Tests

Technical problems with several water bottles caused leakage, thus data from six female
subjects (5 Cre-, 1 Cre+) were removed from this analysis. LPS treatment decreased preference
(percentage of sucrose consumed) for sucrose in all animals (F 1,33 = 32.88, p < 0.001, ηp2 =
0.499). Overall, males had a higher preference for sucrose than females (F 1,33 = 4.761, p = 0.036,
ηp2 = 0.126). No other significant effects or interactions were detected for preference (Fig 4A).
Total consumption was lowered by LPS (F1,33 = 38.959, p< 0.001). This difference was most
likely driven by changes in sucrose consumption rather than water consumption as LPS
decreased sucrose (F 1,33 = 50.111, p < 0.001, ηp2 = 0.603) but not water consumption (Fig 4 B,
C). There was also a Treatment x Genotype interaction (F 1,33 = 4.64, p = 0.039, ηp2 = 0.123), and
a trending effect of genotype (F 1,33 = 3.796, p = 0.06, ηp2 = 0.1) for sucrose consumption. Follow
up post-hoc tests for genotype effects show Cre+ animals (combined sexes) consumed more
sucrose than Cre- animals after saline treatment (t = -2.27, p = 0.031), but not after LPS
treatment (t = 0.20, p = 0.84). There were no other significant effects or interactions for sucrose
consumption (Fig 4B). Body weights for all animals, taken immediately before injection, did not
differ by treatment or genotypes, but, unsurprisingly, males were heavier than females (FSex 1,33 =
41.29, p < 0.001, ηp2= 0.51) (Table 1).
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Figure 3-4
Sucrose and water consumption and preference. Mean ± SEM of (A) preference score
(percentage of sucrose consumption compared to total consumption), (B) consumption (mL) of
2.5% sucrose solution, and (C) consumption (mL) of water for male and female Cre- (white
bars) and Cre+ (filled bars) groups. Points indicate individual data. Horizontal bars indicate
treatment differences and genotype differences
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Time spent immobile, latency to first immobile period, and the number of immobile
periods were measured in the tail suspension test (TST). Males spent more time immobile than
females (FSex 1,38 = 4.893, p = 0.033, ηp2 = 0.114); there were no other effects detected. There
were no effects on latency to first immobile period. LPS treatment caused an increase in the
number of immobile periods (FTreatment 1,38 = 4.534, p=.040, ηp2=.107); there were no other effects
on immobile periods. (Table 1).
Table 3-1
Body weight and tail suspension test data. Mean ± SEM for body weight at time of
injection and TST measures.

Measure

Male

Male

Male

Male

Female

Female

Female

Female

Cre-

Cre+

Cre-

Cre+

Cre-

Cre+

Cre-

Cre+

Sal

Sal

LPS

LPS

Saline

Saline

LPS

LPS

27.00
Body

27.08 ±

26.82 ± 27.46 ± ±

23.67 ±

23.14 ±

24.17 ±

23.29 ±

weight

1.706

1.537

Time

168.54 ± 155.72

immobile

31.16

2.367

2.431

2.103

1.215

1.850

1.604

155.93

178 ±

151.2 ±

156 ±

130.76

134.55

42.18

39.82

± 44.9

± 29.25

± 31.57 ± 42.72 29.1

Latency to
first

26.06

immobile

31.93 ±

37.75 ± 29.89 ± ±

51.48 ±

51.67 ±

32.13 ±

41.62 ±

period

18.55

19.56

37.96

50.44

24.18

25.92

20.95

18.96
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Number of

14.64

immobile

12.62 ±

13.36 ± 13.31

±

10.08 ±

12.33 ±

13 ±

13.33 ±

periods

2.84

3.35

4.589

2.54

3.386

5.170

4.179

3.4.3

±2.84

Sociability tests

. All subjects preferred investigating an animal over an object following both LPS and
saline treatment (Saline F 1,37 = 38.538, p < 0.001, ηp2 = 0.510; LPS F = 21.895, p < 0.001, ηp2 =
0.372). In saline-treated animals, there was a trend towards an interaction of Stimulus by
Genotype by Sex (F 1,37 = 3.59, p = 0.066). There were no other significant effects or interaction
in saline conditions (Fig 5). LPS effects lasted at least one day, as LPS-treated animals showed
significantly fewer zone crosses the day following injection than did saline-treated animals
(12.34±7.97 vs. 24.32±7.29, mean ± SEM.; F 1,37 = 64.47, p < 0.001, ηp2 = 0.64).
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Figure 3-5
Social Preference Test. Data for Saline and LPS treatments are presented separately.
Mean ± SEM of active investigation (s) of both object (white bars) and same-sex stimulus animal
(filled bars) during the social preference test. Points indicate individual data. Horizontal bars
indicate investigation differences.
To test subjects’ preference for social novelty, the object was replaced with a novel
stimulus animal. For saline-treated subjects, there was a main effect of stimulus (F 1,37 = 20.56, p
< 0.001, ηp2 = 0.36), and an interaction of Stimulus by Genotype by Sex (F 1,37 = 4.916, p =
0.033, ηp2 = 0.117). In males, there was a main effect of stimulus (F1,22 = 10.79, p = 0.003) and
an interaction of Stimulus by Genotype (F1, 22 = 5.56, p = 0.028). To further elucidate this
interaction, post-hoc t-tests were conducted for each genotype; Cre- males showed a preference
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for the novel animal (t = -4.9, p = 0.0004), while Cre+ males did not (t = -.55, p = 0.59). In
females, there was a main effect of stimulus (F1,16 = 9.11, p = 0.008) but no interaction of
Stimulus x Genotype. There were no other main effects or interactions in saline-treated animals.
After LPS treatment, there was no preference for either the novel or original stimulus across
subjects (Fig 6). Once again, LPS effects lasted at least one day, as LPS-treated animals showed
significantly fewer zone crosses the day following injection than did saline-treated animals (9.12
± 6.90 vs., 18.63 ± 5.14, mean ± SEM.; F 1,37 = 56.41, p < 0.001, ηp2 = 0.60)

Figure 3-6
Social Novelty Preference Test. Data for Saline and LPS treatments are presented
separately. Mean ± SEM of active investigation (s) of both original (white bars) and novel (filled
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bars) same-sex stimulus animals during the social novelty preference test. Points indicate
individual data. Horizontal bars indicate investigation differences.

3.4.4

Testing order

We compared behavioral results between animals that received LPS first with those that
received saline first. We did not find an effect in the majority of measures, except that in the first
block of the OFT, saline-treated animals in the second trial (which received LPS in the first trial)
traveled slightly less distance (F1,39 = 4.955, p=.032) than saline-treated animals in the first trial,
irrespective of genotype. Additionally, all tail suspension measures, which were not affected by
treatment or genotype, were affected by testing order (Time Immobile: F1,38 = 18.35, p < 0.001 ;
Latency: F1,38 = 29.65, p < 0.001; Immobile Periods: F1,38 = 9.63, p = 0.004). This suggests that
only the TST was significantly affected by repeated testing.
3.5

Discussion
Although previous studies have suggested that BNST AVP cells in rats may play a role in

reducing sickness behavior (e.g., 62), our results in mice do not align with this; if anything, males
were affected opposite to our prediction. For example, ablating BNST AVP cells reduced
sickness behavior in response to LPS in males. The same treatment significantly altered other
behaviors in control conditions. Specifically, it reduced preference for social novelty in males
and increased sucrose intake in both sexes. Therefore, these data support the idea that BNST
AVP cells play a more prominent role in male than in female behavior, but they do not suggest a
critical role in LPS-induced sickness behavior.
LPS reliably induced sickness behavior, seen especially as reductions in mobility and
increases in anhedonia, but did so in all animals, irrespective of BNST AVP cell ablation. If
BNST AVP cells reduce sickness behavior, one would expect that removal of these cells enhance
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behavioral effects of LPS. On the contrary, ablating BNST AVP cells mitigated the effects of
LPS treatment on speed of locomotion in the elevated zero maze in males. However, ablating
these cells in females produced effects in the predicted direction, enhancing the reduction in
speed after LPS treatment. While this sex difference is still in line with the sex- and steroiddependent function of these cells, if AVP significantly modulates sickness behavior in mice as it
does in rats, it suggests that other AVP-expressing systems, such as the paraventricular nucleus
of the hypothalamus (PVN) and suprachiasmatic nucleus (SCN), may be more significant
players. PVN cells, including a large number of its AVP-expressing cells, respond to LPS with
increased fos activation 55. A central role of the PVN in sickness behavior is also suggested by
studies showing correlated changes in behavior and neurochemical parameters in the PVN
following LPS treatment 8,155. Likewise, the SCN is an important regulator of immune
responding, as lesions of this structure exacerbate reactions to LPS 68. Additionally, the SCN
sends AVP projections to nuclei that regulate behaviors changed by LPS injection, such as the
PVN, BNST, and medial preoptic area 57, and is therefore well positioned to play a role in
sickness behavior.
Our results do not eliminate a possible role of sex- and steroid-dependent AVP in
sickness, as there are sexually dimorphic AVP populations in the MeA as well as the BNST 61,63,
both of which have been implicated in fever suppression in rats 36–38. Therefore, one may have to
ablate both populations to see a significant effect on sickness behavior as the remaining AVP
cells in the MeA may compensate for the loss of BNST AVP and be sufficient to reduce sickness
behavior in response to LPS. However, ablating BNST AVP cells strongly affected male social
behavior, indicating that these lesions were extensive enough to impair AVP-dependent
behavior.
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Our data add strong evidence for a sexually dimorphic role of BNST AVP cells in the
control of social behavior. As mentioned above, indirect evidence had already implicated these
cells in social behavior. For example, injections of AVP antagonists 46,66,67,100,156 or V1aR gene
manipulations 64,65 affect social behavior, often in a sex-dependent manner. As we previously
reported, BNST AVP cell deletion generates deficits in social communication in males only 131.
Here we find BNST cell ablation in males eliminates social recognition memory as measured by
a bias for investigating novel individuals (social novelty preference), without changing social
interest.
The effects of BNST AVP cell ablation on behavior found in the present study cannot be
unequivocally linked to sexually-dimorphic AVP expression as we removed whole cells, which
not only express AVP but also other neuroactive substances, such as galanin 157,158, which also
contributes to social behavior 159. Consequently, behavioral effects may be caused by removal of
AVP, co-transmitters, or both. However, since this manipulation eliminated male social
recognition, a behavior that depends on AVP within BNST projection sites 46,64–67,160, it is likely
that our results are due primarily to removal of BNST AVP production.
Unexpectedly, BNST AVP cell ablation caused an increase in sucrose consumption in
both males and females. While it is possible that this increase is due to increased fluid intake,
this is not likely because water consumption was not altered by cell deletion. It is also possible
that this increase was driven by increased hunger or overactivity. However, subjects whose
BNST AVP cells were ablated did not differ from controls in body weight or activity levels
during behavioral tests, suggesting no difference in caloric intake or energy expenditure. Perhaps
these cells can modulate hedonic drive, such that their removal increased the desire for sucrose.
Subnuclei of the BNST respond to sucrose with changes in dopamine and norepinephrine release
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, so it is possible that AVP cells may contribute to sucrose reward. At any rate, the effects of

BNST AVP cells on sucrose consumption suggest a wider role for these cells than just
modulation of social behaviors.
3.5.1

Conclusions

Given the sex- and steroid-dependent nature of BNST AVP cells, we expected to find sex
differences in the effects of their ablation on behavior, with males exhibiting greater impacts
than females. AVP had been previously shown to reduce sickness behaviors, specifically in
males, with the BNST indirectly implicated as a source for this effect. Our data, however,
suggest that these cells are not critical for reducing LPS-induced sickness behavior, but they are
critical for recognition of social novelty in males. This highlights the BNST, and specifically its
AVP cells, as critical nodes for male social behavior.
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REDUCTION OF VASOPRESSIN CELLS IN THE SUPRACHIASMATIC

NUCLEUS IN MICE INCREASES ANXIETY AND ALTERS FLUID BALANCE
Jack Whylings, Nicole Rigney, Geert J de Vries, Aras Petrulis
JW designed and performed experiments, analyzed data, and wrote manuscript, NR
contributed to experimental design and provided assistance in conducting and analyzing
experiments. GJdV and AP contributed to experimental design, advisement, writing, and
provided resources.
4.1

Introduction
Animals do not live in isolation; they must respond to both internal and external contexts

in order to thrive and reproduce. These needs are met by a combination of homeostatic
physiological mechanisms and behavioral interactions. For many organisms, including humans,
social behavior is critical for survival, and must be tuned to multiple contexts. One
neuromodulatory system heavily involved in regulating both physiology and behavioral outputs
is arginine vasopressin (AVP), a nonapeptide neuromodulator and hormone. AVP from various
sources57, such as the paraventricular nucleus of the hypothalamus (PVN), the bed nucleus of the
stria terminalis (BNST), the supraoptic nucleus (SON), and the suprachiasmatic nucleus (SCN),
is important for regulating stress responses, anxiety, social behaviors, and water balance47,100,162–
164

.
Additionally, AVP contributes to sickness: the body’s response to infection and

inflammation. Activation of the immune system causes multiple physiological and behavioral
changes, such as fever, altered metabolic processes, reduced activity, social withdrawal, and
anhedonia1,3,5. AVP mpdulates some of these changes, for example, AVP from the BNST and
medial amygdala regulates fever in male rats36–38,51. Previous work in our laboratory has shown
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that PVN AVP contributes to changes in motivated behaviors, such as anhedonia, during
sickness caused by lipopolysaccharide (LPS), a gram-negative bacterial coat protein83. AVP is,
therefore, well-positioned to act in concert with other inflammatory-responding systems to
generate physiological and behavioral sickness responses.
The source of AVP that regulates social and anxiety-like behaviors, in both healthy and
sick contexts, is primarily AVP-expressing cells in the PVN and BNST, and most studies have
centered on these two regions. However, another major source of centrally-projecting AVP, the
SCN165,166, may also contribute to these behaviors. SCN AVP cells project to multiple midline
nuclei, such as the PVN, paraventricular thalamus, dorsomedial hypothalamus, and preoptic
nucleus57,167, as well as within the SCN168. SCN AVP cells are critical for coordinating biological
clock function169,170 and behavioral circadian rhythms77,79,171, and have been implicated in
regulating food intake80 and circadian thirst81,172,173. However, the role of SCN AVP in regulating
emotional and social behavior has not been as extensively studied.
In addition to circadian rhythms, the SCN as a whole regulates inflammatory responding.
Circadian rhythms alter responses to immune stimuli174,175, and immune challenges can disrupt
circadian rhythms70,75,176. Disruptions of the SCN, ranging from dim light exposure during the
dark phase76 to ablation of the entire SCN68, increase the inflammatory response to endotoxin
challenges. Although LPS has been shown to increase AVP release from SCN cells82, it is
unknown whether SCN AVP is involved in regulating sickness behaviors.
Due to the role of AVP in anxiety and social behaviors48,67,121,156, the function of the SCN
in regulating inflammatory responding, and the SCN AVP projections to behaviorally-important
hypothalamic nuclei, we assessed the role of SCN AVP cells in social and emotional behavior
across two experiments. In the first experiment, we measured the effects of selectively ablating
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SCN AVP cells on anxiety and social behaviors. In the second experiment, we examined whether
deletion of SCN AVP cells would alter sickness behavior and so we injected subjects with either
LPS or saline in a counterbalanced design, and then tested them on anxiety-like, depressive-like,
and social behaviors.
4.2

Methods
4.2.1

Animals

All mice were maintained at 22°C on a 12:12 reverse light cycle with food and water
available ad libitum, housed in individually ventilated cages (Animal Care Systems, Centennial,
CO, USA), and provided with corncob bedding, a nestlet square, and a housing tube. All animal
procedures were approved by the Georgia State University Institutional Animal Care and Use
Committee (IACUC) and were in accordance with the regulations and the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
4.2.1.1 Subjects
AVP-IRES2-Cre-D (AVP-Cre) mice were obtained from The Jackson Laboratory (Stock
No: 023530; Bar Harbor, Maine, USA). AVP-Cre knockin mice have Cre recombinase
expression directed to vasopressin-expressing cells that are restricted to populations within the
hypothalamus. Subjects were derived by crossing heterozygous Cre+ mutants to wildtype
C57Bl/6J mice and genotyped (ear punch) by polymerase chain reaction (PCR) at 21-24 days of
age (Transnetyx, Cordova, TN, USA). Both Cre+ and Cre- littermates were used in behavioral
experiments. A total of 54 experimental animals were tested: 14 Cre- males, 11 Cre- females, 16
Cre+ males, and 13 Cre+ females.
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4.2.1.2 Stimulus Animals
Stimulus animals,C57B6/J and CD-1 mice of both sexes, were housed in same-sex
groups. CD-1 female stimulus mice were ovariectomized and implanted subcutaneously with a
Silastic implant of estradiol (0.7 cm active length; 1.02 mm inner diameter, 2.16 mm outer
diameter, Dow Corning, Midland, MI, USA; 1:1 estradiol benzoate:cholesterol). Before any
testing for sex behavior (social experience and copulatory behavior, as described below), female
stimulus mice were injected with .1mL progesterone (500 μg dissolved in sesame oil, Sigma, St.
Louis, USA) to induce behavioral estrus. Male CD-1 stimulus mice were gonadectomized, and
group housed. A subset of male CD-1 stimulus mice, receiving subcutaneous implants of
testosterone (0.7 cm active length; 1.02 mm inner diameter, 2.16 mm outer diameter, Dow
Corning, Midland, MI, USA; crystalline testosterone, Sigma, St. Louis, USA) and singly-housed,
were used for providing social experience and copulatory behavior. Surgery and implant
procedures were performed as described previously in detail in prior publications103,131.
4.2.2

Social Experience

All subjects received social experience (described in detail in prior publications103,131)
prior to viral vector injections as sexual and aggressive experiences promote communication
behaviors in mice177,178 Subjects received sexual and aggressive experience in four separate
instances; each sex experience was followed by an aggressive experience; there was at least one
day between the first and second sets of sex-aggression experiences.
Sexual experience was provided by placing a sexually-experienced, hormone-implanted,
opposite-sex CD-1 stimulus mouse overnight in the subjects’ home cage (first experience) or for
ninety minutes (second experience). For aggressive experience, subjects were exposed to a samesex, non-territorial (gonadectomized and group-housed), CD-1 mouse as an intruder in the
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subject’s home cage. The stimulus animal was removed after the subject’s first offensive attack
(biting) or after ten minutes if no fighting occurred. Female subjects were exposed to female
intruders; however, this did not elicit attacks from either animal.
4.2.3

Viral Vectors

AVP driven-, Cre-expressing SCN neurons were ablated using an adeno-associated virus
(AAV; serotype 2/1 (3x1012 IIU/mL) AAV-flex-taCasp3-TEVp; UNC Vector Core) that
encodes, in a Cre-dependent fashion, a mutated pro-caspase-3 and its activator (TEVp). This
system activates an apoptotic signaling cascade, cleaving multiple structural and regulatory
proteins critical for cell survival and maintenance146,147 and killing cells with far less collateral
inflammation than other lesion approaches103,148.
4.2.4

Stereotaxic surgery

All surgeries were carried out using 1.5-3% isoflurane gas anesthesia in 100% oxygen; 3
mg/kg of carprofen was given before surgery to reduce pain. Mice were positioned in a
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) with ear and incisor bars
holding bregma and lambda level. After a midline scalp incision, a hand operated drill was used
to make holes in the skull, exposing the dura. For all subjects, 250 nl of AAV-flex-taCasp3TEVp was delivered bilaterally to the SCN (coordinates: -.2 mm AP; +- 1.73 mm ML; -5.74 mm
DV, 15 degree angle) (Paxinos and Franklin, 2012) at a rate of 100 nl/min using a 5 μl Hamilton
syringe with a 30-gauge beveled needle mounted on a stereotaxic injector. Following virus
delivery, the syringe was left in place for 15 minutes and then slowly withdrawn from the brain.
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4.2.5

Experiment 1: Effects of ablation of SCN AVP cells on social and emotional
behaviors

All testing occurred within the first eight hours of the dark cycle under red light
illumination. All tests were scored by an experimenter blind to the genotype of the subject. On
experimental days, subjects were adapted to the experimental room for fifteen minutes prior to
testing. First, we tested mice on an elevated plus maze to test for anxiety-related behavior. Mice
were then tested in the three-chamber apparatus over five days. Lastly, copulatory and aggressive
behavior were measured sequentially in the subject’s home cage. Female subjects were tested
irrespective of estrous cycle day, except during copulation testing, when they were in behavioral
estrus, confirmed by analysis of vaginal cell morphology.
4.2.5.1 Elevated-Plus Maze
The elevated plus maze (EPM) consisted of two open arms (30 x 5 x 0 cm) and two
closed arms (30 x 5 x 25 cm) crossed perpendicularly and raised 60 cm above the floor. Subjects
were placed in the intersecting center zone and were habituated to the apparatus for one minute;
subjects' behavior was scored over the following five minutes. Due to software failure, results
from a subset of animals could not be reliably quantified; behaviors from the remaining animals
(9 Cre- males, 5 Cre- females, 8 Cre+ males, 5 Cre+ females) were recorded with a digital video
recorder, and scored by an observer using Noldus Observer software (XT 11). Behaviors
measured include time spent in open and closed arms, open arm entries, and the number of risk
assessment behaviors (stretch-attend posture, head-dips; Rodgers and Cole 1993). Three subjects
(2 Cre- males, 1 Cre+ male) were removed from EPM data analysis because they fell off the
maze during testing.

58
4.2.5.2 Social Behavior
Ultrasonic vocalizations (USV), urine marking, and social investigation were recorded in
an acrylic three-chamber apparatus (Harvard Apparatus, Holliston, MA, USA; dimensions: 20.3
x 42 x 22 cm). Subjects were all acclimated to the apparatus over 2 days of exposure (2 mins) to
the testing area and 3-chamber apparatus. During the 3 days of behavior testing, mice were first
exposed to the apparatus with no stimuli in either chamber; the following 2 testing days subjects
were exposed to male and female stimulus animals in separate tests. Instead of a solid floor, the
apparatus was placed on absorbent paper (Nalgene Versi-dry paper, Thermo Fisher Scientific,
Waltham, MA, USA) so as to accurately measure urine marking. During testing with stimulus
animals, subjects had access to either a CD-1 stimulus animal in a cylindrical cage (8 cm (D), 18
cm (H); 3 mm diameter steel bars, 7.4 mm spacing) or an empty cage placed in the outer
chambers of the apparatus. Subjects and stimulus animals had limited ability to directly contact
each other; they were able to pass extremities (e.g. paws, tail) through the smaller cage bars
during investigation. The location of stimulus and the “clean” cage were counterbalanced across
animals. After placing the subject in the center of the middle chamber, we measured, across a 5minute trial, close investigation of clean and stimulus cages, as well as USV and urine marking,
as described below. After testing, the apparatus and cages were thoroughly cleaned with 70%
ethanol and allowed to dry before further testing. The order of male and female stimuli
presentation was counterbalanced across subjects.
4.2.5.3 Social Investigation and Ultrasonic Vocalizations
Close investigation of stimulus cages was defined as time spent sniffing within 2 cm of
each cage. USV were detected using a condenser microphone connected to an amplifier
(UltraSoundGate CM16/CMPA, 10 kHz - 200 kHz, frequency range) placed 4 cm inside the
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apparatus and directly above the center compartment. USV were sampled at 200 kHz (16-bit)
with target frequency set to 70 kHz (UltraSoundGate 116Hb, Avisoft Bioacoustics, Berlin,
Germany). Recordings were then analyzed using a MATLAB (MATLAB, Mathworks,
RRID:SCR_001622) plug-in that automates USV analysis (MUPET179). Using this program,
sonograms were generated by calculating the power spectrum on Hamming-windowed data and
then transformed into compact acoustic feature representations (Gammatone Filterbank). Each
200-millisecond window containing the maximum USV syllable duration was then clustered, via
machine learning algorithms, into USV syllable types (repertoire units) based on time-frequency
USV shape. Repertoire units that appeared as background noise were discarded. As the number
of USV syllables produced is low in this strain, we limited our analysis to the total number of
USV syllables produced during each test.
4.2.5.4 Urine Marking
Following testing, each substrate sheet was allowed to dry and was then sprayed with
ninhydrin fixative (LC-NIN-16; Tritech Forensics Inc., Southport, NC, USA) to visualize urine
marks. After twenty-four hours, sheets were imaged with a digital camera and then analyzed
using imaging software (ImageJ, RRID:SCR_003070). Visualized marking was outlined and
areas measured and summed. Urine marking was measured as the total area (pixels) of visualized
ninhydrin urine marks in the entire arena. Urine marks that were larger than 6 cm2 and directed
toward corners were counted as elimination ‘pools’ and were removed from analysis.
4.2.5.5 Copulatory and Aggressive Behavior
To measure copulatory behavior, the stimulus mouse was placed in the subject’s home
cage for ninety minutes. The latency to mount, latency to intromit, number of mounts and
intromissions, and percent of male ejaculations were recorded. To measure territorial aggression,
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stimulus animals were placed in the subject’s home cage and then removed after the subject’s
first offensive attack (biting) within a ten-minute period; the latency to this attack was recorded.
4.2.5.6 Odor Discrimination
At the end of experiment 1, a subset of subjects (9 Cre-, 5 Cre+) were tested for their
olfactory ability using a habituation-discrimination approach that measured whether subjects
could distinguish between social and non-social odors. Animals were repeatedly exposed (five
times; two minute trials; 1 minute intertrial intervals) in their home cage to filter paper
containing one odorant. Afterwards, the stimulus was replaced with a different odor which was
then also repeatedly presented. Subjects were first exposed to distilled water, then to one of three
non-social odors (lemon extract, almond extract, coconut extract, Kroger, Cincinnati OH, USA),
then to a second non-social odors (counterbalanced), followed by a social odor (male or female
urine), and then by the other social odor (female or male urine, counterbalanced). We compared
the amount of time Cre+ and Cre- subjects spent investigating each odor between the first and
last presentation of each odor and then between the last presentation of the familiar odor and the
first presentation of the novel odor, using mixed-model ANOVA (investigation time as a withinsubjects factor, genotype as a between-subjects factor)
4.2.6

Experiment 2: LPS-induced sickness behavior

At least one week after the behavioral tests in Experiment 1, subjects were tested for
sickness behaviors. Subjects were weighed and injected intraperitoneally with either 0.5 mg/kg
LPS (from e. coli 0111:B4, Sigma, St. Louis, MO, USA) or sterile saline one hour before dark
phase (ZT11). As described in previous experiments, the open field test (OFT) was conducted
three hours following LPS injections, and the elevated zero maze (EZM) test was conducted
immediately following the OFT. Sucrose preference was then assessed in the home cage during
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the following 24-hour period. The day after LPS or saline injections, subjects were tested during
the dark phase in the three-chamber apparatus for social preference and novelty detection.
Subjects were tested twice, first within ~24 hours after LPS/Saline, then again one week later
after Saline/LPSin a counterbalanced manner. In all cases, animals were acclimated to the
behavior testing suite for at least one hour before testing, and tests were done during the dark
phase under dim red lighting.
4.2.6.1 Open-Field and Elevated Zero Maze
Three hours after LPS injections, animals were placed in a 43 cm x 43 cm x 30 cm open
field chamber for 10 min and behavior was automatically tracked via infrared beam breaks (Med
Associates, Fairfax, VT, USA). Distance traveled and time spent in the (anxiogenic) center area
were analyzed as measures of locomotion and anxiety-like behavior, respectively. Immediately
after OFT, subjects were tested on an elevated zero maze (EZM). This apparatus consists of a 5.5
cm wide circular platform (internal diameter 35 cm) raised 50 cm off the ground, with two
equally spaced enclosed compartments covering half of the platform. Video was manually scored
(Noldus Observer) by an observer blind to subject genotype for time spent in both open and
closed arms as a measure of anxiety-like behavior, and for zone crosses (subject crossing from
open to closed arm and vice versa) as a measure of activity.
4.2.6.2 Sucrose Preference
For at least 2 days before LPS/saline injections, subjects were acclimated to having two
water bottles placed in their home cage. After OFT/EZM assessment, subjects were returned to
their home cage, and bottles were replaced with pre-weighed bottles, one containing sucrose
solution (2.5% in tap water) and the other tap water. Animals had access to both sucrose solution
and water for the next 20 hours, until the start of the next day’s testing. The bottles were then
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removed and weighed to measure consumption. A control water bottle in a nearby empty cage
showed a <1 g loss over the same period and room conditions. Sucrose consumption, water
consumption and preference, calculated as the percentage of sucrose consumed of total
consumption (Sucrose / (Sucrose + Water) *100%), were analyzed.
4.2.6.3 Social Preference and Social Novelty Preference
To measure social preference and social novelty, animals were tested in the threechamber apparatus as described above, 26 hours after LPS injection. Subjects were placed in the
apparatus for 5 min before testing to habituate the subjects to the environment and were then
temporarily removed while stimulus animals/objects, contained within smaller cages (8 cm
diameter, 18 cm height, 3-mm diameter bars, 7.4 mm spacing) were placed in the center of each
of the two outer chambers. First, to test for social preference, a novel toy object (either a mouse,
robot, or small car figurine) and a novel same-sex C57 stimulus animal were placed in opposite
cages. Subjects and stimulus animals had limited ability to directly contact each other; they were
able to pass extremities (e.g. paws, tail) through the smaller cage bars during investigation. The
subjects were then returned to the apparatus and allowed 10 min to explore the apparatus. At the
end of this test, the subjects were removed again, and the toy object replaced with a novel
stimulus animal (from a different cage from the first stimulus) to test for recognition of social
novelty. The subject was then placed into the center chamber again and given 10 min to explore
the apparatus. The position of object and original animal was counterbalanced across trials but
did not change between social preference and social novelty preference tests. Videos were
manually scored (Noldus Observer) by an observer blind to subject genotype for outer chamber
entries as a measure of activity, time spent in each chamber, and close investigation, defined by
the subject’s snout within 2 cm of the stimulus cage.
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4.2.7

Histology and In Situ Hybridization

Following all testing, subjects were killed via CO2 asphyxiation. Brains were extracted
and flash-frozen via submersion in 2-methyl-2-butanol (Sigma, St. Louis, MO, USA) for 10-20 s
and stored at −80°C until sectioned into 3 series of 20 μm. Tissue was sectioned and labeled for
AVP mRNA (accession number NM_027106.4) via fluorescent in situ hybridization as described
in detail in previous work103,131. Bilateral images of the SCN were taken at 20x magnification
using a Zeiss Axio Imager.M2 microscope (Carl Zeiss Microimaging, Göttingen, Germany), and
analyzed using ImageJ. The SCN was outlined, and fluorescent cells were manually counted in
each hemisphere of the SCN. Cell counts and SCN area were summed and averaged across each
animal to generate an overall SCN cell/area metric which we then compared across ablated and
control subjects. Ablated subjects were included in the analysis if they had > 30% SCN AVPexpressing cell ablation overall and >50% deletion within at least one hemisphere.
4.2.8

Data Analysis

In Experiment 1, the EPM data were analyzed for effects of genotype using independent
t-tests; urine marking, USV, sex behavior, and aggressive behavior were analyzed separately by
sex for effects of genotype. Data that did not meet requirements for parametric testing were
transformed using a Box-Cox procedure (urine marking) or analyzed using a nonparametric
Kolmgorov-Smirnoff test (USV). Social investigation was analyzed using a mixed-model, fourway ANOVA, using stimulus identity (animal or empty cage) and stimulus sex (male or female
trials) as within-subject variables, and genotype (Cre+, Cre-) and subject sex (Male, Female) as
between-subject variables.
In Experiment 2, data from OFT, EZM, and sucrose preference testing was analyzed
using a mixed-model, three-way ANOVA, using treatment (LPS, Saline) as within-subjects
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variable and both subject sex and genotype as between-subject variables. Investigation in the
Social Preference test was analyzed using a four-way mixed model ANOVA with the same
parameters as the prior tests and inclusion of stimulus identity as a within-subjects variable.
Results with p-values equal to or less than 0.05 were considered statistically significant,
and results with p-values of 0.05 to 0.09 were considered trending effects. Degrees of freedom
were not adjusted in our mixed model ANOVA analyses as all data sets maintained sphericity
(Mauchly’s test of sphericity). Post-hoc t-tests were used to analyze genotype differences
following significant ANOVA main effects and interactions. In addition, we calculated Pearson’s
correlation coefficients to analyze the relationship between SCN AVP cell loss and behavior,
using the number of remaining SCN AVP cells/mm2 in Cre+ subjects. All statistical analysis
was conducted using SPSS 27 (IBM)
4.3

Results
4.3.1

Fluorescent in situ hybridization and cell ablation

Viral expression of Cre-dependent caspase caused a marked AVP cell reduction in the
SCN. Cre+ subjects were kept in the analysis if there was at least a 30% reduction of cell
count/area as compared to Cre- controls. 4 Cre+ males and 6 Cre+ females were removed for not
meeting this criteria. The average reduction in ablated Cre+ animals was 53.55 +- 3.75 % of
controls. There was a significant difference between the cell count/area of Cre- and Cre+
subjects (t-test, t = 7.003, p < 0.001, d = 2.19). Cell reductions occurred throughout the anteriorposterior axis of the SCN, with no clear directional bias. Figure 1 shows representative
photomicrographs of AVP labeling in a Cre- and Cre+ subject. No behavioral measures were
significantly correlated with the number of remaining SCN AVP cells.
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Figure 4-1
AVP fluorescent in situ hybridization. Example photomicrograph of one unilateral SCN
(outlined) in both (A) a Cre- control animal and (B) a Cre+ animal with 52% AVP cell
reduction.
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4.3.2

Experiment 1

4.3.2.1 Elevated Plus Maze
Cre+ animals spent significantly less time in the open arms of the elevated plus maze (t =
2.67, p = 0.014, d = 1.09), and more time in the closed arms of the maze (t = 2.51, p = 0.023, d =
1.03). Cre+ animals produced fewer head dips (t = 2.74, p = 0.012, d = 1.12), but did not
decrease the amount of stretch-attends compared to controls (t = -0.21, p = 0.83). The total
number of entries into all zones (a measure of general activity) did not differ between genotypes
(t = -.494, p = 0.63).

Figure 4-2
Anxiety-like behaviors in the elevated plus maze. Mean ± SEM of (A) time spent in the
open arms, (B) number of stretch attend postures, and (C) number of head dips for Cre- (white
bars) and Cre+ (gray bars) subjects. Points represent individual data from males (blue points)
and females (red points); asterisks represent significant (p < 0.05) genotype differences.

4.3.2.2 Social Investigation
For all subjects, there was a significant difference between investigation of the empty
cage and the stimulus cage. All subjects spent more time investigating social stimuli than the
empty chamber (F = 45.395, p < 0.001), with a trending interaction of subject sex (F = 3.922, p =
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0.055). There were no other significant main effects or interactions of subject genotype or
stimulus sex. Neither sex (F = 0.64, p = 0.43) nor genotype (F = 1.14, p = 0.29) altered total
investigation time of empty chambers during the initial no-stimulus trial.
As mouse communication behavior varies significantly based on the sex of both the
subject and stimulus103,131, urine marking and USV were analyzed seperately for both sexes and
each trial (no stimuli, male stimulus, female stimulus). In response to the clean environment,
Cre+ males deposited more urine than Cre- males (t = 2.583, p = 0.02); there was, however, no
genotype differences between female subjects in urine deposition (t = -.314, p = 0.759). Urine
marking to social cues (male or female stimuli) did not differ according to genotype in male or
female subjects. Genotype did not alter urine marking of either sex during investigation of male
(Male subjects t = -0.405, p = 0.689; Female subjects t = -0.008, p = 0.994) or female (Male
subjects t = -1.121, p = 0.273; Female subjects t = 0.571, p - 0.779) stimluls trials.
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Figure 4-3
Investigation of male and female stimuli. Mean ± SEM of investigation time of male (A,
C) and female (B, D) stimulus animals compared to a clean cage by male (A, B) and female (C,
D) subjects in both Cre- (white bars) and Cre+ (filled bars) subjects. Points represent individual
data and asterisks represent significant (p < 0.05) investigation of stimulus animals.
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Figure 4-4
Urine marking. Median and interquartile range of urine marking area (mm2) when
subjects were presented with no stimuli (A, D), male stimuli (B, E), and female stimuli (C, F), for
both male (A, B, C) and Female (D, E, F) subjects. Points represent individual subjects. Outliers
that are greater than the scale of boxplots are represented as numbers rather than data points.
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4.3.2.3 Sex, Aggression, Odor Discrimination
There were no significant differences between genotypes of either sex in copulatory
behavior (number or latency of mounts, intromissions, or ejaculations) or offensive aggression
(latency to attack).
All subjects showed habituation in their investigation to repeated exposures to both nonsocial (first non-social odor test: F = 8.55, p = 0.012; second non-social odor test: F = 50.781, p
<0.01) and social odors (first social odor test: F= 81.12, p <0.01; second social odor test: F =
51.891, p <0.00 ), with no significant main effect of genotype. All subjects also discriminated
between non-social odors (F = 12.95, p = 0.004), between social odors (F = 42.219, p <0.001),
and between a non-social and social odor (F = 160.00, p <0.001), with no main effect of
genotype, indicating that reduction in SCN AVP cells did not cause significant deficits in basic
odor processing.
4.3.3

Experiment 2

4.3.3.1 Open Field (OFT) and Elevated Zero Maze (EZM)
In the OFT, treatment with LPS reduced time spent in the anxiogenic center zone by all
subjects (F=17.786, p < 0.001); two subjects did not move from their initial placement in the
testing environment and so were removed as outliers (both were >3 standard deviations above
the mean). There was a trend towards a sex difference, with males spending slightly more time in
the center than females (F = 3.870, p = 0.056), but no other main effects or interactions were
detected in the OFT. LPS treatment also reduced distance traveled, a measure of overall activity
(F = 731.515, p < 0.001), with no other significant main effects or interactions. Unexpectedly,
treatment with LPS did not alter time spent in the open arms in the EZM; however, LPS
treatment did decrease the number of entries into the open arm (F = 90.81, p <0.001), with a
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trending interaction of sex (F = 3.849, p = 0.057). There were no other significant main effects or
interactions in EZM test metrics.

Figure 4-5
Anxiety-like behavior and locomotion in the open field test and elevated zero maze. Mean
± SEM of (A) time in the center zone and (B) distance traveled in the OFT; (C) time in the open
arms, and (D) number of entries into the open arms in the EZM for Cre- (white bars) and Cre+
(gray bars) subjects after LPS and saline treatment. Points represent individual data from males
(blue points) and females (red points); asterisks represent significant (p < 0.05) treatment
differences.
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4.3.3.2 Sucrose Preference Test
Treatment with LPS reduced preference for sucrose compared to water (F = 31.805, p
<0.001), with no effect of genotype or sex. Both sucrose consumption (F = 210.618, p < 0.001)
and water consumption (F = 12.623, p = 0.001) were reduced by LPS injections. However, only
the consumption of sucrose showed a significant effect of genotype (F = 5.540, p = 0.024) and a
trend toward a treatment by genotype interaction (F = 3.753, p = 0.06). Cre+ animals consumed
more sucrose than Cre- controls, although this did not affect the overall preference percentage.
There were no significant effects of genotype on water consumption, and no main effects or
interactions with sex on any measure. Additionally, there was no genotype effect on body weight
(F = 0.001, p = 0.973), although there was an expected sex difference (F = 47.293, p < 0.001).
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Figure 4-6.
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Fluid Consumption and Sucrose Preference. Mean ± SEM of (A) sucrose preference
percentage, (B) sucrose solution consumption, and (C) water consumption during the sucrose
preference test for Cre- (white bars) and Cre+ (gray bars) subjects after LPS and saline
treatment. Points represent individual data from male (blue points) and female (red points)
subjects; asterisks represent significant (p < 0.05) treatment differences in all three measures,
and significant genotype differences in sucrose consumption.

4.3.3.3 Social Preference tests
In the social preference phase of testing, subjects showed a preference for investigating
the animal stimulus over the object stimulus (F = 49.549, p < 0.001), with a significant
interaction between treatment and stimulus identity (F = 6.656, p = 0.014). Subjects investigated
the animal stimulus over the object in both saline (t = 6.183, p < 0.001) and LPS (t = 6.826, p <
0.001) conditions. In the social novelty phase of testing, subjects investigated the novel stimulus
animal more than the familiar animal (F = 12,744, p = 0.001), with a significant effect of LPS
treatment (F = 8.055, p = 0.007), and an interaction between treatment and stimulus (F = 5.179, p
= 0.028). Subjects spent more time investigating the novel stimulus animal than the original
stimulus animal in both saline (t = -2.472, p = 0.018) and LPS (t = 3.308, p = 0.002) conditions.
LPS treatment did significantly decrease the number of chamber entries, a measure of general
activity, across tests (F = 153.823, p < 0.001).
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Figure 4-7.
Close investigation in social preference tests. (A) Mean ± SEM of time spent investigating
the object stimulus (white bars) and animal stimulus (gray bars) in the social preference test for
both Cre- and Cre+ subjects after LPS and saline treatment. (B) Mean ± SEM of time spent
investigating the original animal stimulus (white bars) and novel animal stimulus (gray bars) in
the social preference test for both Cre- and Cre+ subjects after LPS and saline treatment. Points
represent individual data from male (blue points) and female (red points) subjects; asterisks
represent significant (p < 0.05) differences in stimulus investigation.

76
4.4

Discussion
Substantial reduction in the number of SCN AVP cells caused an increase in anxiety-like

behavior and sucrose consumption in both sexes, and increased urination in male mice only.
Reductions of AVP cells in SCN did not have measurable effects on social behaviors, social
communication, odor discrimination or intensity of sickness behaviors. These results highlight a
specific role for this cell population in modulating anxiety and perhaps in regulation of water
balance.
AVP cells within the SCN were significantly reduced by our manipulation, but not
entirely eliminated. The remaining AVP cells may be sufficient to maintain the function of this
cell population and so we cannot eliminate possible contributions of SCN AVP to social
behavior or sickness regulation. SCN AVP cells are primarily GABAergic180–182. Therefore, the
effects we observed after SCN AVP cell reduction may be due to loss of inhibition or other
neuropeptides co-released from these cells rather than the loss of AVP signaling; more specific
targeting of AVP would be required to confirm its function within the SCN.
AVP within the SCN serves to coordinate its cellular clocks77,78, and so behavioral effects
of SCN AVP cell reduction may be due to altered circadian rhythms. Studies comparing anxietylike behavior in the elevated plus maze (EPM) during active (dark) and inactive (light) phases
have found effects of cycle phase on measures of general activity, such as arm entries but not the
time spent in open or closed arms183,184. Indeed, ablation of SCN AVP cells did not alter overall
activity, suggesting that the observed effects on anxiety-like behavior were likely not due to a
lesion-induced shift in phase. Moreover, circadian shifts in SCN AVP cellular rhythms only alter
behavioral activity rhythms in free running conditions77,171, rather than in the consistent 12:12
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light cycle conditions under which our subjects were housed. This consistent light acts as a
strong zeitgeber, which would have prevented substantial shifts in activity patterns.
Reduction of SCN AVP cells caused a significant increase in anxiety-like behaviors
(decreased time in open arm, reduced exploratory head dips) in the EPM, but not when later
tested in the open-field test (OFT) or the elevated zero-maze (EZM). However, both of these
tests were conducted after the EPM, and so subjects were exposed to considerably more handling
and testing prior to OFT/EZM testing. As handling, injections, and repeated testing in anxiogenic
environments can all reduce subsequent measures of anxiety185–187, it is possible that this
habituation effect reduced our ability to detect changes in anxiety-like behavior in these later
tests.
The increase in anxiety-like behavior after SCN AVP ablation may be driven by its
projections to the dorsomedial hypothalamus (DMH) and/or subnuclei of the paraventricular
nucleus (PVN)57,170. These projections, particularly those targeting inhibitory interneurons
surrounding the PVN and those in DMH, could directly or indirectly alter PVN and HPA axis
activity170. For example, changes in SCN AVP can both increase or decrease AVP content within
the PVN, depending on PVN cell type; reducing AVP in SCN increased AVP expression in
magnocellular neurons but decreased it in parvocellular neurons188. Consequently, reducing SCN
AVP may increase anxiety through activation of the HPA axis, or from reductions in neural
projections from parvocellular AVP cells. Notably, Cre-dependent ablations of PVN AVP cells
caused similar increases in anxiety in the EPM as observed in the present study83,103, suggesting
that SCN AVP projections may work via AVP cells in PVN to regulate anxiety.
Reduction of SCN AVP cells in both males and female mice increased their consumption
of sucrose in the sucrose preference test but did not change their sucrose preference or water
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consumption. Increased sucrose consumption may indicate an increase in caloric drive, as SCN
AVP inhibits food intake80. However, there was no weight gain after SCN AVP ablation, which
would be expected if food intake was increased overall. This suggests that reducing SCN AVP
increases the hedonic value of sucrose and, therefore, increases the motivation to consume
sucrose189. Both water intake and sucrose consumption follow a circadian pattern190, with higher
drinking during the active phase (dark phase, ZT 12-24 in mice) than in inactive (light) phase. As
SCN AVP expression is high during the day and low during the night phase166,191,192, lower AVP
during the active phase may contribute to increased intake of sucrose and would be consistent
with our results. However, SCN AVP release is responsible for an increase in drinking at the end
of the active phase; prevention of this AVP signal eliminates this anticipatory drinking and
results in dehydration after rest81,172. While loss of SCN AVP decreases fluid consumption
during this specific period, our measurement of sucrose intake aggregated consumption over a
24-hour period and observed increased fluid consumption. It is, therefore, possible that loss of
anticipatory drinking causes slight dehydration followed by a compensatory increase in overall
fluid intake. Alternatively, our results may reflect differences in neural regulation of motivation
to consume sucrose or other palatable substances independent from anticipatory thirst.
While sucrose intake was increased in both sexes, increased urination was only seen in
males after SCN AVP ablation; these males increased production of urine marks in an empty,
clean environment compared to control animals without a significant increase in urine marking
to male or female stimuli. A sex difference in urination is unsurpsing, given that males mark
more than female in previous studies using this paradigm103,131 and that sex effects
urination193,194. However, there is typically minimal urination in a no-stimulus/clean
environment103,131; suggesting that increased urination observed is not indicative of alterations in
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social communication. It may be that a disruption in fluid balance, or disruptions in peripheral
AVP release may be responsible for this increased urination; AVP rhythm disruptions contribute
to conditions such as nocturnal enuresis in humans195,196. Increased urination after SCN AVP
ablation does not indicate diabetes insipidus, as seen in examples of whole-body AVP loss 197,198,
although it does suggest some role for SCN AVP in regulating fluid homeostasis.
SCN AVP has been studied for its roles in regulating circadian biology, both in
maintaining cellular rhythmicity in the SCN and in maintaining circadian rhythms in output
regions. Our results highlight an additional role for SCN AVP in regulating anxiety behaviors,
potentially through regulation of PVN AVP. Additionally, these results indicate that SCN AVP
contributes to sucrose consumption; however, it is not clear whether these effects are due to
changes in reward processing or alterations in circadian drinking behavior.
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5

CONCLUSIONS

Targeted ablation of three distinct AVP cell populations provides insight into the roles of
these cells in regulating anxiety and social behaviors, modulating motivational changes in
sickness, and contributing to hedonic drive. PVN AVP cells regulate anxiety behavior and
regulate social preference and sucrose preference during sickness. BNST AVP cells regulate
male social behavior, as multiple lines of evidence suggest; additionally, BNST AVP cell
regulate sucrose consumption in both sexes, suggesting a role for these cells in non-social
motivation. SCN AVP cells regulate anxiety-like behaviors and sucrose consumption in both
sexes, and contribute to male urination. AVP is well known for its regulation anxiety and social
behaviors, and these data further support this role of AVP; these data also suggest a role for AVP
in non-social motivation by regulating sucrose consumption.
In all of the direct manipulations of AVP cells, entire cells were deleted, including coneurotransmitters, such as glutamate199, GABA180,182,199, galanin104,157,158,200, and other co-factors
expressed in AVP cells. Our results may be due to the loss of these co-factors and changes in
excitatory or inhibitory tone in addition to AVP; further work, targeting AVP specifically would
be needed to confirm AVP as necessary for these changes. These manipulations also could have
triggered compensatory mechanisms, both from other cells in the targeted nuclei, and other AVP
populations with shared projection regions, resulting in reduced efficacy of cell deletion. For
example, peripheral release from an AVP source such as the SON may have maintained some
functions of AVP and obscured effects of cell ablations. Targeting multiple AVP populations
may result in stronger behavior effects; for example, ablating both PVN and SCN AVP cells may
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cause more robust increases in anxiety behaviors than seen in the data from individual targeting
of these regions.
LPS reliably induced sickness behavior, but the robust behavioral changes may have
introduced ceiling effects, obscuring potential roles for AVP in sickness behaviors. If loss of
AVP enhances sickness behavior, this may have gone undetected in instances where LPS greatly
reduced behaviors such as locomotion. Preliminary data (unpublished) suggest that AVP mRNA
expression may be altered in the PVN and SCN by chronic, low-grade inflammation; this may
indicate a role for AVP outside of responding to immediate, acute illness, but needs further
study.
5.1

Neuroanatomical Subdivisions of AVP Functions
5.1.1

Paraventricular Nucleus AVP Cells

The results from PVN cell ablation support a role for PVN AVP in tempering sickness
after LPS challenge. In these experiments, PVN AVP removal enhanced the effects of sickness,
primarily on anhedonia, but also on social preference, predominantly in males. PVN AVP is
produced broadly in two populations of cells, releasing AVP peripherally through the pituitary or
centrally through PVN afferents to other neuronal structures63,112. Unlike the PVN of the rat, the
mouse PVN does not have clear morphological or anatomical divisions of these cell types, and
both projections may contribute to the behavior seen112. AVP, in conjunction with corticotropin
releasing factor (CRF) upregulate glucocorticoids42,93, which inhibit pro-inflammatory cytokine
production and suppress immune responding56. Loss of AVP from this system may suppress the
typical increase of glucocorticoids after inflammatory challenge, and thus exacerbate the
sickness behaviors seen here201,202. Further studies of physiological factors, such as serum levels
of glucocorticoids and cytokines, and markers of increased neuroinflammation, would show the
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role of PVN AVP in regulating inflammation. While general increased inflammation may be
responsible for the enhanced effects of sickness behaviors seen after PVN AVP ablation, they
may also be caused by changes in central projections. While the BNST is the main source of
AVP fibers to the septal nuclei, a critical social behavior node122, the PVN does contribute to
AVP release in the lateral septum (LS)57. This projection may be a route for altering social
behaviors, specifically in stressful contexts such as sickness.
PVN AVP reductions in sucrose preference support a role for these cells in depression
and hedonic processing. Increases in PVN AVP is associated with depression in humans,
contributing to HPA axis dysfunction42,94,203; our results suggest that PVN actions during
inflammation may oppose inflammation-induced anhedonia. Anhedonia and depressive like
behavior can be induced through multiple models, such as inflammation, chronic stress, social
defeat stress, and early-life manipulations204; PVN AVP effects on anhedonia may be dependent
on the contexts of depression-inducing stressor. PVN AVP may also effect sucrose preference
through actions on reward circuitry; PVN AVP projects to the nucleus accumbens (NAc), the
reward processing center of the brain57,117; and AVP acting in the NAc has been implicated in
drug reward, although its function has not been thoroughly defined118–120. This may indicate a
role for PVN AVP in regulating hedonic reward, and specifically may increase motivation to
consume sucrose in opposition to other inflammatory mechanisms causing anhedonia. Targeting
of AVP functions in these projection sites may confirm the role of PVN AVP and what circuitry
is responsible for these behaviors
5.1.2

Bed Nucleus of the Stria Terminalis AVP Cells

The effects of BNST cell ablation do not support the hypothesis of these cells'
involvement in sickness behavior. For the majority of behaviors measured, LPS clearly caused
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sickness behavior, with minimal changes under BNST cell ablation. This may suggest that BNST
AVP actions on sickness are limited to physiology, such as fever38. Data showing BNST AVP
regulation of male fever are from studies in rats; it is also possible that mouse AVP does not play
the same roles in inflammatory responding. Studies replicating the physiological effects of AVP
in mouse fever would be needed to show a role for these cells in physiological regulation of
sickness. Apart from sickness, BNST AVP cell ablation shows a role for these cells in regulating
social behavior and sucrose consumption. Normal social behaviors in males are dependent on
BNST AVP, and our results are in line with the known functions of hormone-sensitive
AVP46,65,67, in that removal of AVP impairs social recognition by reducing preference to
investigate a novel conspecific. Additionally, ablation of AVP BNST cells increased sucrose
consumption, while not altering other aspects of fluid or energy balance in this or a prior
study131. Other subnuclei of the BNST respond to sucrose reward161 and may provide a path for
BNST AVP to regulate sucrose consumption. Unlike most effects of BNST AVP manipulation,
this effect was seen in females as well as males, and may be independent of testosterone
dependent BNST AVP expression.
5.1.3

Suprachiasmatic Nucleus AVP Cells

SCN AVP ablation did not alter sickness behaviors in this study, and our results do not
support the hypothesis that SCN AVP regulates sickness behaviors. While the SCN as a whole is
involved in balancing inflammatory responding69,71, reduction of AVP cells specifically did not
enhance sickness behaviors. This indicates that other SCN populations are critical for sickness
responding, more AVP cell loss is needed for behavioral effects, or SCN AVP is not involved in
behavioral sickness. Studies measuring pro-inflammatory cytokines, in both serum and neural
tissue, may reveal roles of AVP cells in physiological immune regulation. As SCN AVP is
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important for clock coordination77, experiments in which animals are allowed to free-run in
constant lighting conditions may be necessary to detect some effects of AVP cell deletion,
especially those driven by circadian disruptions. Ablation of these cells did alter some behaviors
even under a consistent light cycle, highlighting functions of SCN AVP. AVP cell loss increased
anxiety-like behavior in the EPM; this may be due to projections to the PVN57,205 and SCN
regulation of PVN AVP188. Stressors increase SCN AVP release206,207, but the behavioral action
of this AVP release is not known; this study suggests SCN AVP reduces anxiety-like behaviors.
SCN AVP ablation also increased sucrose intake and male urine output. These effects may be
related to circadian control of fluid balance via SCN projections to the vascular organ of the
lamina terminalis (OVLT)57,172; however, in contrast to our results, other studies suggest AVP
increases water intake81. Clock genes, specifically Per, have been implicated in circadian
patterns of sucrose intake and expression of clock genes in striatum and cortex190; AVP
coordination of the clock, or clock gene regulation of SCN AVP rhythms208, may regulate the
relationship between SCN AVP and reward consumption. Further experiments that focus on
AVP actions on water and sucrose intake throughout the cycle, instead of at one specific time
point or summed over 24 hours, would be necessary to better understand the relationships
between AVP, clock genes, thirst, and sucrose reward.
5.2

Behavioral Consequences of AVP Cell Deletion
While each of these experiments highlight distinct roles of AVP in separate nuclei, they

also provide evidence for central AVP as a regulator of social behavior, anxiety-like behavior,
and hedonic consumption. These may be due to shared projection nuclei and actions on
vasopressin receptors, for instances where ablation of different cell populations causes similar
effects. In contrast, AVP actions at different nuclei may also contribute to different behavioral
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functions or possibly cause opposing behavioral effects. While targeting of AVP receptors or
specific AVP terminals would be necessary to determine the behavioral roles of each AVPergic
circuit, the results of cell ablation indicate promising targets for control of the behaviors
measured in these experiments.
5.2.1

Social Behavior

BNST and PVN ablations both altered male social behavior, but in slightly different
manners. BNST AVP is expressed primarily in males, while PVN AVP is equally expressed in
both sexes; therefore it is not surprising to see male-biased effects from BNST manipulations,
but male biased effects from PVN AVP ablation point to sex-differences in AVP projection sites.
AVP actions in the LS are important for typical male social behavior65,67,156,209; while the
majority of AVP afferents to the LS are from sexually dimorphic populations such as the BNST
and medial amygdala (MeA), the PVN does provide sparse projections to the LS57. While
ablation of both BNST and PVN AVP cells altered social behavior, changes were on different
qualities of social preference. BNST cell ablation eliminated the normal preference to investigate
a novel animal stimulus, providing further evidence for these cells in social motivation and
recognition. In contrast, PVN cell ablation caused elimination of the normal preference to
investigate a novel social stimulus over a non-social object, but only during sickness. This
suggests that PVN AVP role in social behavior may depend on stressful contexts. Due to the
shared projection site of the LS, it is a prime target for manipulating AVP receptors and
terminals to better clarify the roles that BNST and PVN each contribute to social behavior.
5.2.2

Anxiety-like Behavior

AVP regulates anxiety-like behaviors via both PVN and SCN AVP. In a prior study with
PVN ablated animals, AVP cell ablation caused increased anxiety in the elevated plus maze103,
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similar to the effects seen after SCN AVP ablation. However, for ablations of both nuclei, later
tests of anxiety-like behavior, the open field test and elevated zero maze, did not show a baseline
increase in anxiety after cell ablation, other than a remaining correlation between extent of PVN
cell ablation and reduced time in the center of the OFT. This suggests that while AVP ablation
increases anxiety, this effect is reduced with repeated testing and experience. Repeated testing
and handling can reduce anxiety185–187, and is likely driving the loss of effects on later tests of
anxiety-like behaviors.
SCN and PVN AVP are not independent, as both populations influence AVP expression
in the other. SCN AVP projects to the PVN57, contributes to the circadian rhythm of the HPA
axis170, and influences PVN AVP expression. In rats, SCN AVP reductions cause increased AVP
in magnocellular PVN cells, and decreased AVP in parvocellular PVN cells188. Conversely,
glucocorticoids, regulated by HPA axis activity, can increase AVP expression in the SCN210,211.
In these AVP cell ablation studies, both PVN and SCN cell ablations caused similar increases in
anxiety-like behavior and suggest a shared system of action. This is at odds with studies that
show a positive correlation between PVN AVP and anxiety like behavior, for example, high
anxiety trait mice expressing greater AVP than low anxiety trait mice48,49. This discrepancy may
be due to variations in AVP cell populations, much as how SCN AVP induces opposite effects
on different PVN AVP cell populations. While both pituitary- and centrally-projecting PVN
AVP cells were deleted83,103, our results suggest that reductions in centrally-projecting PVN
AVP, whether from loss of PVN AVP cells or as a result of reduced SCN AVP inputs, increase
anxiety-like behaviors. More specific targeting of the SCN to parvocellular-like PVN cells and
their central output would be necessary to test this hypothesis.

87
5.2.3

Sucrose Consumption

AVP cell ablation in all three experiments caused changes in sucrose consumption,
indicating a widespread role for AVP in regulating sucrose consumption. AVP deletion in the
PVN reduces sucrose preference during sickness, while AVP deletion from both the BNST and
SCN increases sucrose consumption in healthy animals. Sucrose preference has been used as a
model of anhedonia in models of depression, chronic stress, and sickness behavior, and
reductions in sucrose preference are reversible by antidepressant actions on dopamine
systems6,212–215. Hedonic aspects of “liking” and “wanting” may be separated in analysis of
sucrose preference data, with preference percentage used as a measure of liking, while
consumption of sucrose indicates wanting189,216, which would implicate SCN and BNST AVP in
motivation to consume sucrose. V1aR antagonism opposes stress-induced reductions in sucrose
preference and consumption217; this aligns with increased sucrose consumption after AVP cell
deletion. However, PVN AVP deletion further reduced sucrose preference during sickness,
showing that AVP actions on sucrose preference are not entirely consistent. AVP actions in the
ventral pallidum, a salience-processing nucleus218, have been implicated in social reward and
motivation219; this role may also extend to regulating non-social motivation. Research into AVP
actions on drug-seeking and reinforcement may better clarify how AVP interacts with
dopaminergic reward circuitry.
While there is limited work on AVP’s role in stimulant drug taking, Godino and
Renard220 have developed a preliminary hypothesis on AVP actions in reward circuitry that is
consistent with our data on sucrose consumption. They suggest that AVP acts directly in the NAc
to reinforce drug seeking, while AVP actions outside the NAc opposes dopamine increases to the
NAc during drug-taking. Cocaine and amphetamine administration increases AVP expression in
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the NAc, and blocking AVP receptors inhibits conditioned cocaine responses119,120. In contrast,
amphetamines decrease AVP release in the LS221, increasing LS AVP inhibits amphetamineinduced place preference222, and intracerebroventricular AVP inhibits cocaine selfadministration223. While sucrose reward is not similar to abused stimulants, our results align with
the hypothesis of AVP actions on reward. Loss of PVN AVP, which projects to the NAc, reduces
sucrose preference and consumption, and while this is detected solely during sickness, still
suggests a role of PVN AVP in motivating sucrose consumption. Conversely, loss of AVP from
the BNST and SCN increased sucrose consumption, indicating that AVP release from these cells
may act to reduce motivation to consume sucrose, similarly to how AVP outside the NAc may
reduce rewarding salience of drugs of abuse.
5.3

Future Directions
There are many opportunities to further expand on the roles of AVP discussed here in

future experiments. These can involve studies into physiological sickness and other models of
inflammation such as chronic, low grade inflammation. Specific actions of AVP can be better
understood by more precise targeting, such as reducing AVP gene expression or AVP receptors
and terminals. Finally, much more work is needed to better understand a role of AVP in
regulation of non-social motivation and reward.
Overall, our observations found minimal effects of AVP cell deletion on acute sickness
behaviors; however, these cells may have influence over other aspects of inflammatory response.
To avoid undue stress during behavioral testing, we did not examine serum factors or
temperature throughout the inflammatory response, which could be altered after AVP ablations.
Examining AVP-mediated effects on cytokine expression, glucocorticoid release, body
temperature, and microglia activation in the 24-hours following LPS administration would
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provide a picture of how AVP may influence sickness physiology. Of the cell populations
studied, the PVN is most likely to regulate physiological factors, due to its regulation of the HPA
axis, and that we observed effects of PVN AVP cell deletion on behavioral sickness. BNST and
SCN may both be involved in fever and temperature regulation, and studies examining these, and
potentially projections to the POA, may show a role for AVP cells in fever.
Other models of sickness may also reveal different functions of AVP cells. Preliminary
data (unpublished), suggests that AVP expression in the PVN and SCN changes during lowgrade, chronic inflammation, which has also been used in studies of sickness behavior224–226 and
is more similar to depression-inducing illness in humans than a single, acute bacterial infection.
AVP may have a role in regulating longer term changes or recovery from sickness, and less
influence on immediate responses. Additionally, other ways of stimulating the immune system,
such as activating viral-sensing immune cells or direct administration of pro-inflammatory
cytokines, may reveal functions of AVP not seen after acute LPS administration. Less intense
sickness behavior may also avoid the potential ceiling effects discussed previously.
Experiments in our lab are targeting AVP gene expression and direct output sites using a
variety of modern techniques, and these will provide essential data to understanding the specific
functions of AVP circuits. Targeting AVP expression directly, using shRNA, allows replication
of cell ablation results while eliminating potential effects of co-released factors (pilot data shows
knockdown of BNST AVP using shRNA, Rigney). Optogenetic terminal stimulation227,228, and
application of AVP agonists and antagonists229 can provide detail on AVP actions in specific
projection sites. Manipulations of AVP receptors using similar methodologies will also be useful
in examining functional consequences of AVP actions as they relate to anxiety-like behaviors,
social behaviors, and sucrose consumption.
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Future research is also needed to better understand the role of AVP in hedonic
motivation. AVP effects on sucrose preference indicate some role of these cells in motivation,
and may indicate a role for AVP in motivation to consume sucrose189. Other behavioral
paradigms, such as placement preference, and tasks designed to determine willingness to work
for a reward, would be needed in concert with AVP manipulations to better understand how AVP
regulates non-social motivation. Uses of modern techniques, such as the ones our laboratory is
using to study the roles of AVP in social communication, may be applied to tests of non-social
motivation. Characterization of how AVP agonism and antagonism influence both liking and
wanting of rewards would be necessary as a foundation before in-depth circuit manipulations.
5.4

Conclusion
Ablations of AVP cell populations have provided insights into the functions of these cells

in regulating a range of behaviors, from expected alterations in social behavior to providing new
evidence for AVP actions in hedonic consumption. PVN AVP specifically is involved in
modulating motivation during sickness; while BNST and SCN AVP cell ablation did not alter
sickness expression, further research into physiology and other forms of sickness are needed to
determine what role, if any, these cell populations play in regulating sickness. BNST, and to a
lesser extent PVN, AVP cells regulate male social behavior, while SCN and PVN AVP cells
regulate anxiety-like behaviors. AVP cell deletion in the PVN, BNST, and SCN alter sucrose
consumption, highlighting an important role for AVP in non-social, hedonic motivation; this is
an interesting and understudied function of AVP, and provides a target for better understanding
of how this neuropeptide maintains behavioral states.
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